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Abstract 
Neuroblastoma is the most common extracranial solid tumor in childhood. It constitutes 
an interesting model for tumor progression since the mutation rate is relatively low as 
compared to other tumors, allowing to investigate specific tumor drivers in a relatively 
homogeneous genetic background. One of the important drivers of tumor formation in 
neuroblastoma is the oncogene MYCN. This transcription factor is responsible for the 
activation of a cascade of genes involved in cell proliferation and metabolism The study 
of MYCN’s role in these processes is highly relevant because a deep understanding of 
the regulation could lead to more effective therapies for MYC-driven tumors. In this PhD 
thesis, an approach was developed to study cell cycle and metabolism on MYCN-driven 
neuroblastomas. One of the caveats of cell cycle studies is the lack of markers to study 
cell cycle transition, and the artifacts caused by cell synchronization. By combining the 
E2F1-d2GFP and Cdt1-degron markers it was possible to identify a G0-like state, which 
is more prominent upon reduction of MYCN. This state is transient and it was not 
possible to detect it before in this cell system. The cells under high MYCN expression 
avoid passing through the G0-like state. This decision happens early in the cell cycle 
and it is not influenced by p21, contrary to what was found in other studies. Gene 
expression profiling of sorted cells using the cell cycle markers demonstrated that the 
transcriptional program of G0-like state caused by MYCN reduction is different from 
mitogen starvation and contact inhibition, suggesting that the G0-like state might be a 
spectrum of states with similar phenotypes but distinct expression profiles. As an 
outlook, the network analysis of the expression data suggests RABL6 as a potential 
marker of MYCN that controls the commitment to cell cycle by inhibiting p16, however 
further experiments are required to confirm this finding. From the metabolic perspective, 
we found that MYCN-high cells are strongly addicted to the amino acid cystine, which 
serves as a source for the glutathione pathway. Inhibition of enzymes from this pathway 
shows a dramatic lethal effect exclusively on MYCN-high cells. We found that the 
mechanism of cell death under cystine starvation in MYCN-amplified cells is ferroptosis, 
a recently described pathway that involves lipid peroxidation enhanced by iron. To our 
knowledge, this is the first time that MYCN is associated with ferroptosis which opens an 
avenue for developing new drugs targeting MYC-driven tumors via induction of 
ferroptosis. 
	iv		
Zusammenfassung 
Das Neuroblastom ist der häufigste während der Kindheit auftretende extracraniale 
solide Tumor. Da es verglichen mit anderen Tumoren eine relativ niedrige Mutationsrate 
hat, stellt es ein interessantes Modell zur Erforschung der Tumorentwicklung dar und 
ermöglicht die Untersuchung spezifischer Tumortreiber vor einem relativ homogenen 
genetischen Hintergrund. Einer der wichtigsten Faktoren der Tumorbildung im 
Neuroblastom ist das Onkogen MYCN. Dieser Transkriptionsfaktor reguliert die 
Aktivierung einer Kaskade von Genen, die an Zellproliferation und Metabolismus 
beteiligt sind. Ein tiefes Verständnis der Funktionen und Regulierung des Onkogens 
MYCN in diesen Prozessen ist unabdingbar, um daraus effektivere Therapien für MYC-
getriebene Tumore ableiten zu können. Im Rahmen dieser Doktorarbeit wurde ein 
Verfahren entwickelt, um den Zellzyklus und Metabolismus von MYCN-getriebenen 
Neuroblastomen zu untersuchen. Fehlende Marker für die einzelnen Zellzyklusphasen 
und Artefakte aufgrund von Zellsynchronisation schränken Zellzyklusstudien stark ein. 
Durch Kombination von E2F1-d2GFP und Cdt1-degron-Marker war es möglich, einen 
G0-ähnlichen Zustand zu identifizieren, der insbesondere nach MYCN-Reduzierung 
aufgetreten ist. Es handelt sich hierbei um einen vorübergehenden Zustand, der zuvor 
noch nicht in diesem Zellsystem detektiert/beschrieben werden konnte. Zellen mit einer 
hohen MYCN Expression vermeiden den G0 ähnlichen Zustand. Diese Entscheidung 
wird bereits sehr früh im Zellzyklus getroffen und nicht, wie in früheren Arbeiten 
beschrieben, durch p21 beeinflusst.  Genexpressionsanalysen von durch die oben 
genannten Zellmarker sortierten Zellen, zeigten, dass das Transkriptionsprogramm des 
durch MYCN- Reduzierung induzierten G0-ähnlichen Zustandes sich von den durch 
Mitogenmangel und Kontaktinhibition verursachten Zuständen unterscheidet. Dies lässt 
vermuten, dass es sich bei dem G0-ähnlichen Zustand um ein Spektrum von Zuständen 
mit ähnlichem Phänotyp, aber unterschiedlichen Expressionsprofilen handelt. 
Netzwerkanalysen der Expressionsdaten legen nahe, dass RABL6 ein potentieller 
MYCN-Marker ist, der die Einhaltung des Zellzyklus durch Hemmung von p16, 
kontrolliert. Allerdings sind weitere Experimente erforderlich, um dies eindeutig zu 
belegen. Des Weiteren haben wir festgestellt, dass Zellen mit einer hohen MYCN 
Expression eine starke Abhängigkeit von der Aminosäure Cystein zeigen, die als Quelle 
für den Glutathion Signalweg dient. 
	v		
Eine Hemmung der Enzyme dieses Signalwegs ist mit  einer äußerst hohen Letalität 
ausschließlich von  Zellen mit hoher MYCN Expression verbunden. Des Weiteren 
konnten wir zeigen, dass es sich bei dem Mechanismus des Zelltods unter Cystein-
Mangel bei Zellen mit erhöhter MYCN Expression um Ferroptose, einen kürzlich 
beschriebenen Signalweg, bei dem Peroxidation durch Eisen verstärkt wird, handelt. 
Nach unseren Kenntnissen wird MYCN an dieser Stelle zum ersten Mal mit Ferroptose 
assoziiert. Dies eröffnet völlig neue Wege für die Entwicklung neuer Medikamente für 
MYCN-getriebene Tumore durch Induzierung von Ferroptose.  
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1. Introduction 
2. Definition of the problem 
2.1. Challenges of cancer therapy  
Cancer is a complex disease with almost all tumors sharing similar characteristics such 
as: unlimited division, protection against cellular stresses, evasion from apoptosis, 
sustained angiogenesis, and metastasis in the advanced cases. Diverse therapeutic 
approaches have been developed through the years to target the hallmarks of cancer,  
but a complete cure is still elusive, and perhaps in only very early diagnosed cases, 
stressing the importance of early detection (Pavet, Portal et al. 2011). Drug development 
in cancer has low success rate as compared to other diseases such as cardiovascular 
diseases. Recent data shows that the probability in developing a successful drug for 
treating cardiovascular diseases is 3 times higher than for anti-cancer drugs (Kamb, 
Wee et al. 2007). Cancer therapy started with initial use of DNA damaging agents that 
could kill high proliferating cells. This came with a cost since cytotoxic agents induced 
serious collateral effects due to destruction of normal cells in the surrounding tissues of 
the tumor. More recently, targeted-therapy has shown a few successful cases. One of 
them is Imatinib, kinase inhibitor used to treat leukemia and Pembrolizumab (Robert, 
Ribas et al. 2014), a recently developed monoclonal antibody used to treat advanced 
melanoma cases. This drug has gained popularity as it was successfully used to cure 
melanoma of United states ex-president Jimmy Carter. The drug now called the Carter’s 
drug, seems promising for patients with Melanoma and BRAF mutation and even a lung 
cancer clinical trial was stopped as it was found that this drug worked exceptionally good 
in lung cancer patients. http://www.nbcnews.com/health/cancer/lung-cancer-trial-
stopped-after-jimmy-carter-drug-stops-tumors-n593726. However the spectacular cases 
obtained with the new target-therapy are still limited since cancer resistance originates 
relatively fast rendering some tumors impossible to treat (Kamb, Wee et al. 2007) 
2.2. Neuroblastoma as a model to study cancer proliferation 
Embryonic tumors are exceptional on its nature as they occur in the early ages as 
compared to regular cancer types that appear in adulthood. According to frequency, 
Neuroblastoma is the most frequent embryonal tumor and it appears in children usually 
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less than 1 year (Brodeur 2003). Neuroblastoma is an special and interesting model of 
cancer as it has the highest rate of spontaneous regression (Figure 1), with around 20% 
of cases suffering remission without any therapeutic regime (Everson 1964, Gatta, 
Ferrari et al. 2012). This surprising fact makes Neuroblastoma an interesting cancer 
model to study the mechanisms that control cell proliferation. The Neuroblastoma cell of 
origin has been hypothesized to be the neural crest. This cell type originates at the 
dorsal neural tube and migrate to give rise to neurons and glia of the peripheral nervous 
system (PNS) and mesenchymal cells like craniofacial cartilage and smooth muscle 
(Green and Bronner 2013). 
	
Figure 1. Incidence of spontaneous regression cases among different tumor types. Percentages 
were calculated based on the data from (Everson 1964). 
Due to its cell of origin, Neuroblastoma arises from the sympathetic nervous system and 
localizes often in the adrenal medulla or paraspinal ganglia. Metastatic neuroblastoma 
usually has poor prognosis and usually the therapeutic approaches include a multimodal 
approach with immunotherapy, surgical resection, and treatment with differentiation 
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6.92% Soft tissue sarcoma
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4.62% Osteogenic sarcoma
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agents such as retinoic acid (Matthay, Villablanca et al. 1999, Berthold, Boos et al. 
2005).  Interestingly the mutational load of neuroblastoma is much lower than other 
tumor types (Alexandrov, Nik-Zainal et al. 2013) this “simplifies” the process of 
mechanistically understand the networks driving tumor progression. Of the few genetic 
alterations in neuroblastoma is the amplification of the oncogene MYCN. This was the 
first biomarker described with actual clinically utility. Amplification of this oncogene is 
found in 20% of neuroblastoma cases and it correlates with poor prognosis(Brodeur, 
Seeger et al. 1984). In vivo confirmation of the effects of MYCN showed that it can 
generate tumors upon its overexpression in the sympathetic ganglia (Cheung, Murray et 
al. 2013). MYC oncoproteins are deregulated not only in neuroblastoma but in 
approximately 50% of human tumors (Horiuchi, Anderton et al. 2014). MYC acts as 
global regulator of transcription and it has been found to bind to about 10 to 15% loci of 
the entire human genome (Nie, Hu et al. 2012). Therapeutic approaches in high-risk 
MYCN-amplified neuroblastomas has yielded relatively low success rates (Maris 2010), 
stressing the need for alternative and more effective therapies. 
Other genetic modifications have been found relevant in predicting neuroblastoma 
outcome. Additional genetic markers such as ALK and LMO1 mutations have been 
found to increase disease susceptibility (Mosse, Laudenslager et al. 2008, Wang, Diskin 
et al. 2011). More recently, studies carried out at the collaboration lab found that TERT 
rearrangements are prevalent in approximately 31% of high-risk neuroblastomas with 
MYCN single copy, identifying a new subtype of aggressive tumors with elevated 
expression of telomerase (Peifer, Hertwig et al. 2015).  (See Figure) 
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Figure 2. Neuroblastoma stratification based on TERT expression. Adapted from (Peifer, Hertwig et 
al. 2015). 3n – near triploid, 2n – near diploid, LR – low risk, HR – high risk, MNA – MYCN-amplified. 
(Reproduced with permission from Tatjana Ryl) 
3. MYCN influence in neuroblastoma cell cycle 
MYC has been proposed to be a global regulator of gene expression with around 1000 
target genes and confirmed binding of 15% of genome loci. MYC targets are generally 
activated but a significant set of genes are also repressed by MYC. It was suggested 
that MYC could act as RNA amplifier but more recent evidence did not find this 
regulatory property when comparing quiescent and proliferating cells. This suggests that 
MYC might alter the cellular state which results in increase RNA production (Sabo, 
Kress et al. 2014). The pleiotropic effects complicate the understanding of the different 
mechanisms employed by MYC to surpass growth control. In the context of 
neuroblastoma and MYCN, it is recognized the importance of the genes involved in cell 
cycle and apoptosis. The guardian of the genome, p53, has been involved in repressing 
MYCN expression in neuroblastoma cells, (Torres, Regan et al. 2010), but it could be 
possibly counteracted by the repressive functions of MYCN on p21 promoter. (Gartel, 
Ye et al. 2001). This has important consequences specially when cells are challenged 
by DNA damage agents, as MYCN overrides the DNA damage checkpoint cells are 
more likely to survive and acquire mutations. 
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From the cell cycle perspective, there are some well known targets regulated by MYCN. 
CDK4, a cyclin-dependent kinase is involved in Rb inactivation via phosphorylation and 
MYCN has been shown to directly act on its the promoter increasing the expression 
(Gogolin, Ehemann et al. 2013). More recently, it was found that MYCN regulates SKP2 
expression (Evans, Chen et al. 2015), another important protein involved in cell cycle 
regulation. SKP2 is as well an oncogene and it is frequently overexpressed in human 
tumors.  SKP2 encodes the F-box protein of the ubiquitin ligase SCF-SKP2 complex that 
is comprised of three core proteins RBX1, CUL1, and SKP1. The substrate is bound to 
SKP2 and CSK1 and more than 20 substrates have been found and most of them are 
regulators of G1/S transition. Among them, p27 stands up as the most important 
regulator of the G0-G1 transition. Previous animal models have shown that loss of p27 
and increased expression of c-MYC cooperates in the formation of aggressive tumors. 
Therefore one of the mechanisms of MYC to foster cell cycle entry is the increase of 
pRb (phospho-Rb) and the downregulation p27 via SKP2 upregulation.  (Bretones, 
Acosta et al. 2011) 
However, another study challenged this hypothesis in Neuroblastoma. By using different 
SKP2 promoter constructs to screen for importance of transcriptional sites, 
Westermann’s group found that SKP2 expression is mostly regulated by derepression 
and hyperactivation in MYCN amplified cels. This means that active clearance of Rb-
E2F repressive complex and hyperactivation of SKP2 promoter via E2F is responsible 
for the high levels of SKP2 mRNA observed in MYCN amplified cells.T his mechanism is 
supported by the findings of high CDK4 expression that correlates with  the higher levels 
of pRb found in the presence of MYCN. This is supported also by the idea that low 
mutational rate on RB1 gene is compensated by enhaced inactivation at the protein 
level. (Muth, Ghazaryan et al. 2010) 
Despite its clear influence on cell proliferation, the mechanisms by which MYC and 
similarly MYCN exert the effects on the cell cycle machinery are not well understood. 
MYC overall promotes the expression of cyclins (E and A) and potentially E2F1, with 
E2F1 as well acting on the MYC promoter. MYC has been implicated in preventing 
growth arrest induced by p27 through sustained activation of CDK2. So it seems that 
MYC favors G0 scape but the molecular regulator is still unidentified. In addition, it is not 
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entirely clear where do MYC exerts its strongest effect, if G1 early or G1 late (Mateyak, 
Obaya et al. 1999, Huang and Weiss 2013). In Figure 3 it is summarized the potential 
effects of MYC in cell cycle. 
	
Figure 3. Network representation of MYCN actions on important cell cycle regulators 
4. Regulation of cell cycle entry at restriction point 
CDK4 and SKP2, main targets of MYCN that affect proliferation are specifically involved 
in the regulation of the restriction point in normal cells. The restriction point (RP) is 
defined as the mitogen-sensitve window before cells are committed to cell cycle (Figure 
4A). During this period many different events are occurring to ensure correct passage of 
restriction point, prevention of replicating errors and supplying cells of replicatory 
demands. Many oncogenes in different tumor types exert their effects at the RP in G1, 
but the mechanisms are still unclear (Yao, Tan et al. 2011) 
G1 phase is sensitive to stimulation by mitogens, however when conditions are not 
fulfilled cells enter into another state called quiescence or G0. It is hypothesized that 
cancer cells avoid these controls to remain in the proliferative state, so understanding 
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the mechanisms of restriction point control is central to our understanding of how cancer 
cells proliferate continuously (Sherr 1996). 
The classical mechanism of how RP was described as a sequential inactivation of Rb 
with the boost of E2F1 target genes transcription. In quiescent cells or recently born 
cells E2F1 is bound to Rb and binds the promoters of several genes. Rb-E2F binding 
represses genes involved in DNA replication. Upon certain mitogen threshold which is 
cell type dependent, the MAPK kinase pathway is activated and c-MYC activity is 
increased inducing the expression of Cyclin D1. CDK4/6 are then activated by Cyclin D1 
binding and starts the phosphorylation of Rb. Inactivation of Rb leads to the release of 
E2F and then the transcription of Cyclin E1. E2F1 itself is activated increasing the 
expression of more Cyclin E1, this constitutes the classical positive feedback that results 
in Cyclin E1/CDK2 binding and final inactivation of Rb by phosphorylation (Figure 4B). 
However binding of polypeptide inhibitors to CDK4 and CDK6, the so-called INK4 
proteins, can also actively stop Rb inactivation ultimately causing G1 arrest. The four 
known 15- to 19-kD INK4 proteins (p16, p15, p18, and p19) bind and inhibit CDK4 and 
CDK6, but not other CDKs. INK4 genes are expressed in different tissues suggesting 
they are not redundant. (Sherr 1996). 
Positive feedbacks are the hallmark of bistable switches. To understand the mechanism 
of how the Rb-E2F works on the single cell level, Yao et al developed rat fibroblasts with 
E2F and Cyclin D1 promoter constructs driving GFP expression. Single cell studies help 
to uncover dynamics that might be hidden by average measurements. Serum titration of 
the fibroblasts with and without serum pulse showed that cells on the E2F promoter 
exhibit bimodal behavior. And the transition between the two states (ON and OFF) 
depend on a particular serum threshold that was conserved by repeating the 
experiments about 6 times. (with some variability). On the other hand the Cyclin D1 
reporter only exhibited a unimodal response with levels proportional to the serum dose. 
(Yao, Lee et al. 2008).This results showed for the first time that the restriction point 
works as a bistable switch. 
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Figure 4. The restriction point switch. A) The cell with green nucleus illustrates the reporter used in 
(Yao, Lee et al. 2008) to measure the transition into S phase. Commited cells exhibit full activation of 
E2F1. B) Molecular network that controls passage through restriction point. (See text for details) 
The classical model revealed that it was necessary continuous mitogen stimulation to 
obtain the passage through the restriction point. However an early study observed that 
stimulation with 2 pulses separated by 9 hrs was enough to induce S phase entry (Jones 
and Kazlauskas 2001). This points to the idea that different transcriptional programs are 
required in different parts of G1 for passage through RP. (Pulses EGF) went further to 
described the transcriptional programs and the main finding points towards a phase 
where lipid biosynthesis is started and followed by second phase that leads to fully 
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acitavtion of ERK on the first pulse and finally on the second pulse the activation of PI3K 
that suppresses p53 target genes (Zwang, Sas-Chen et al. 2011). Therefore a clear 
understanding how growth factor signals are transduced to activate Cdk4 and Cdk6 are 
critical medical importance.  
However there are some limitations to the classical RP model. As new experiments are 
being carried out, new functions are uncovered for known cell cycle regulators and in 
some cases those functions are cell type depdent. One interesting example is Cyclin D1. 
It has been always considered as the starting step on the activation of Rb-E2F network. 
However its role still remains controversial. A recent study found that Cyclin D1 might 
play an important role in the machinery of DNA repair (Jirawatnotai, Hu et al. 2011). 
Depletion of Cyclin D1 could sensitize cells to radiation by impairing DNA repair when 
Rb is not present. Interestingly depletion of Cyclin D1 did not affect cell proliferation in 
vivo, only when cells were treated with radiation, growth was retarded, highlighting its 
role in DNA repair. The mechanism described in the study points to a recruitment of 
Cyclin D1 by BRCA2 to the site of damage helping the recruitment of RAD51. Even 
though cyclin D1 is not essential for DNA repair it plays a role in increasing affinity of 
repair machinery to damage sites.  
Rb phosphorylation also brings complexity to the regulation of RP. Rb has 15 
phosphorylation sites that depend on CDKs (Narasimha, Kaulich et al. 2014). The 
biological function of the different sites still remains unknown, although some sites are 
specifically phosphorylated by certain kinases. CDK4, for example, phosphorylates 
S807/S811 in vitro, and deletion of the Cdk4 docking site in RbC abrogates S807/S811 
phosphorylation. Mutation of this site abrogates phosphorylation in additional sites, 
suggesting that S807/S811 is important for overall Rb phosphorylation (Rubin 2013). 
More interestingly, it was observed that Rb is mostly mono-phosphorylated by CDK4/6 
in G1 early in any of the different 14 sites before quantum hyper-phosphorylation by 
CDK2 at G1 late takes at RP, discarding the idea of progressive phosphorylation from 
the classical RP model. However, of how meaningful are the different sites in terms of 
gene regulation remains to be found (Narasimha, Kaulich et al. 2014) 
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Another part of the puzzle not yet defined is the role of by CAK (CDK activating kinase). 
Cyclin D1 binding is a requirement for CDK4 and CDK6 activity. However for full 
activation the phosphorylation by CAKs is required. CDK7 can activate CDK4 and CDK6 
in vitro and deletion of CDK7 leads to reduced activity of CDK4 in mouse fibroblasts. 
However it is not yet defined the role of CDK7 in vivo. More recent results showed that 
CDK7 can activate  both CDK6 and CDK6 under physiological conditions. Interestingly 
CDK2 activation remained after CDK7 was normally turned off but CDK4 activation was 
rapidly lost. Experiments in human cells showed that CDK7 activity increased together 
with CDK4 activity after cells re-enter cell cycle from quiescence, suggesting that CDK7 
and perhaps not much Cyclin D1 are responsible for passage through RP via activation 
of CDK4 (Schachter, Merrick et al. 2013). Even though CDK7 has been involved in 
regulating RP, it has additional functions. It can bind to the transcription factor TFIIH, 
which is involved in transcription initiation therefore regulating global mRNA 
transcription. Interestingly, MYCN has seen to transcriptionally up-regulate genes 
through the usage of super-enhancers, clusters of enhancers that are densely occupied 
by transcription factors, cofactors, and chromatin regulators. When using a covalent 
CDK7 inhibitor (THZ1) the authors found a strong selective cell death on MYCN/c-MYC 
amplified cells. The effect might be mediated to an active suppression of essentially all 
active transcripts, especially those required for uncontrolled proliferation leading to 
potent and selective cytotoxicity while sparing normal cells (Chipumuro, Marco et al. 
2014). 
The RP machinery also presents connection with the p53 axis. E2F1 activation leads to 
a increase expression of Sirt1 which in turns inactivates p53 allowing cells to scape p21 
arrest via p53 induction. However as shown before with the two –pulse regulation of RP, 
this might be time dependent (Wong, Dong et al. 2011). Altogether, the evidence 
suggests that the classical model of RP might need some refinement, including the new 
functions of the cell cycle players involved in RP regulation. 
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4.1.1. Dynamical studies on mechanism of restriction point 
The initial studies of Yao gave insight into RP mechanism by describing it as a bistable 
switch. However questions such as if cell cycle entry depends on the previous cell cycle, 
the duration of the quiescence state, can only be answered by dynamical measurements 
such as live cell imaging. Modifications of initial Yao’s reporter for live cell imaging 
revealed that commitment depends on the amplitude of the E2F1 promoter activity. This 
means that only when E2F1 reaches certain threshold, cells can commit to the cell 
cycle. (Dong, Maddali et al. 2014) 
An elegant study (Spencer, Cappell et al. 2013) measured CDK2 activity in single cells 
and found a bifurcation at the end of the previous cell cycle. The fluorescent sensor 
consists of a segment of human DNA helicase B that contains CDK phosphorylation 
sites and nuclear localization and export signals fused to the yellow fluorescent protein 
mVenus (DHB-Ven). Upon CDK2 phosphorylation the nuclear signal is hidden and the 
fluorescent protein is shuttled to the cytoplasm. The cytoplasmic to nuclear ratio of 
fluorescence intensity can be then used as a readout of CDK2 activity, as validated in 
individual cells emerging from mitogen starvation. The measurements showed that 2 
groups of cells exhibited either low or high CDK2 activity at the moment of birth. The 
bifurcation of CDK2 levels was reported to be dependent on mitogenic signaling in G2 of 
the previous cell cycle. Interestingly the major driver of the bifurcation was p21 in the cell 
lines tested in the study. In principle cells that are born with high p21 levels and low 
CDK2 activity experience a second restriction window in which mitogens are needed to 
re-enter cell cycle and build up CDK2 activity (Figure 5). On the other hand cells with 
CDK2inc (CDK2 high) enter S phase without the need of mitogens as shown by 
inhibition of MEK (Spencer, Cappell et al. 2013). An interesting prediction from the study 
is if cancer cells would mimic the CDK2inc state by changing the proportion of CDK2low 
cells. This question motivated the further experiments carried out in this thesis to find out 
how the RP is regulated in cancer cells. 
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Figure 5. p21 drives bifurcation at mitotic exit. A) The model proposed by (Spencer, Cappell et al. 
2013) indicates that p21 levels in mitosis which is sensitive to mitogens (First restriction point or R1) 
dictate the future fate of cells in the next cell cycle. 1) Low p21 in mitosis allows rapid entry in S phase in 
the next cell cycle without the need of mitogens 2) high p21 can drive a transient state in G0 where cells 
are sensitive to mitogens leading to a second restriction point (R2) or remain in G0 for longer times 
(senescence?). B) Summary of the finds in the proposed model of the restriction point. Adaptated from 
(Spencer, Cappell et al. 2013) 
A follow up study from the CDK2 activity paper explained a more defined mechanism of 
RP regulation. It turns out that irreversibility in RP, meaning the point of commitment and 
start of DNA synthesis independent of a mitogen signal, it is not Rb phosphorylation but 
APC-Cdh1 inactivation driven by Emi1, and this happens long after Rb phosphorylation. 
This suggests that the actual bistable irreversible switch occurs at the boundary of G1/S 
transition and not at the RP as thought before. Another interesting finding is that cellular 
stresses can act upon the period before cells inactivate APC-Cdh1, this leads to cells 
enter quiescence meaning switching off E2F but still remaining sensitive to mitogens. 
However once cells pass the point of no return (or RP) by inactivating APC-Cdh1 with 
Emi1, only damage checkpoints are activated independent of mitogen signaling. 
(Cappell, Chung et al. 2016). The results allow a more precise definition of RP, including 
A B
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the period where cells are sensitive to mitogens up to Rb phosphorylation plus the time 
that leads to final APC-Cdh1 inactivation. 
 
	
Figure 6. Restriction point model involving APC-Cdh1 regulation. The scheme illustrates the 
proposed biochemical RP defined by the inactivation of APC-Cdh1. Adapated from (Cappell, Chung et al. 
2016) 
4.1.2. Molecular definition of G0 phase 
Quiescence or G0 are defined as a state where cells exit the cell cycle and become 
nonproliferative. A practical definition of G0 state has been elusive and sometimes 
confusing among cell cycle literature. One of the reasons is that the molecular 
characteristics of G0 can be variable and there is no consensus in the specific 
transcriptional programs controlling G0 that allow a practical distinction from normal cell 
stress or senescence However it is of medical relevance to molecularly define the G0 
phenotype since chemotherapy selection could potentially enrich for G0 cells. As for the 
case of leukemia, following chemotherapy many patients exhibit minimal residual 
disease, with a subpopulation of leukemia cells that seem under cell cycle arrest, this 
could be caused by chemotherapy itself. However the surviving cells constitute a threat 
since re-awakening of cells might re-populate the tumor or even spread it more 
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aggressively due to random mutations during the G0 state, although this process might 
take long time. (Merlo, Pepper et al. 2006) 
As expected, E2F1 its one of the main negative regulators of G0. Cells that exit G0 and 
enter in S phases start the synthesis of E2F1, passing from being undetectable in G0 to 
high levels equivalent to those in S phase. On the other hand, E2F4 seems to function in 
the opposite role. Unlike E2F1, E2F4 lacks cyclin A binding sites and it is present in 
growth arrested cells. Interestingly, localization of E2F4 is nuclear in G1 early and G0, 
suggesting that it might function as repressive transcription factor. When cells were 
entering S phase, E2F4 was shuttled to the cytoplasm. Whether nuclear E2F-4 acts as a 
transcriptional activator or as part of a repressor complex in different stages of the cell 
cycle remains to be determined (Lindeman, Gaubatz et al. 1997). However, experiment 
in mice showed that E2F1–3 function as transcriptional activators, but are dispensable 
for cell division and instead are necessary for cell survival. However simulatenous loss 
of Rb prevented cells to enter in differentiation state (Chong, Wenzel et al. 2009). 
Together this shows that E2F4 might promote entrance in G0 and E2F1 foster the exit 
from it. To increase the expression of E2F1 and therefore favor the exit from G0 there is 
need of previous Rb inactivation. Interestingly it was found that phosphorylation by 
cyclin C/Cdk3 on S807/S811 phoshphorylation site is necessary for an efficient G0-G1 
transition, but still cells with the mutated site could enter G1 at a lower rate. Even more 
suprising is that Rb phosphorylated in vitro by Cdk3 and microinjected into cells cannot 
inactivate E2F, suggesting cyclin C/Cdk3 phosphorylation of S807/S811 specifically 
mediates G0 exit.  (Macdonald and Dick 2012). 
G0 is usually induced by withdrawal of mitogens, or when mitogens do not reach a 
certain threshold. However other mechanisms could induce quiescence in presence of 
mitogens. When cells in G1 are treated with doxorubicin, drug that induces DNA 
damage, Rb is recruited to the classic repressive pRB-E2F-HDAC complex inducing G0. 
This prevents cell-cycle entry and thus acts indirectly to protect cells from apoptosis. On 
the other hand, in proliferating cells, DNA damage favors formation of the 
transcriptionally active pRB-E2F1-P/CAF complexes because Rb phoshpohorylation 
prevents the formation of repressive complexes. In this setting, pRB favors the activation 
of genes involved in apoptosis. This goes in line with the APC-Cdh1 study, showing that 
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quiescence can only happen in G1. Additionally, reduction of Rb levels impairs Rb’s 
proapoptotic function without altering proliferation (Ianari, Natale et al. 2009).  
 
4.1.3. The transcriptional program of G0 
Previous studies have intended to measure expression profiles in G0 cells versus 
actively cycling cells (Iyer, Eisen et al. 1999, Venezia, Merchant et al. 2004). However, 
as discussed before, quiescence can be induced by different stressors and the 
distinction among them is important to define a global transcription program of G0. 
These kind of analysis will lead to answer questions such as 1) Is it G0 one particular 
state or different states with similar phenotypic characteristics?, 2) is G0 actively 
maintained? 3) Is there such a thing as G0 transcription program?.  
A more recent study (Coller, Sang et al. 2006) tried to address this problem by 
measuring expression profiles in three independent growth arrest signals, and for 
various periods of time. Interestingly, at least for fibroblasts, G0 seems to be a collection 
of states rather than a unique state but it appears there is a global signature common to 
all different states. Mitogen withdrawal upregulated the expression of G-protein 
molecules, MAPK and inositol-triphosphate– signaling pathways as well as IGFBP3, 
perhaps as a compensatory mechanism to stabilize IGFs and promote growth. 
Interestingly, contact inhibition induced downregulation of PCNA, lamin B, CENPA, 
enzymes from nucleotide metabolism and splicing factors, genes mostly involved in 
DNA replication and mitosis. Loss of adhesion, on the other hand, induced 
downregulation of cyclin E1, Cul-1, and FGF4, genes driving G1/S transition. Together 
this shows that different regulators of G0 might exist with specific regulatory programs. 
Interesting at later time points (4 days) the genes became uniformly regulated and a 
stable transcriptional program unique for each growth arrest signal became more 
evident. Mitogen withdrawal led to a persistent downregulation of POLD2, and POLR2I, 
genes involved in nucleic acid synthesis together with EIF3S9 and HARS involved in 
protein synthesis. TGF-b pathway was also involved to a lesser degree. E2F4, 
described before as a potential regulator of G0, was predominantly and uniquely upr-
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egulated in the contact-inhibition condition. Lastly, loss of adhesion affected the 
expression of phosphatases involved in the MAPK pathway. Thus, the events that drive 
G0 seem to be more complex, so that might explain why certain signals do not favor 
cells to exit G0. Another important point will be to understand the role of oncogenes 
fostering cells to scape G0 since this can become relevant to eradicate cancerous G0 
cells. Perhaps the G0 states might be as well different in the in vivo case, which 
deserves further investigation. 
Other genes found to be downregulated are ones related to APC and SCF. This goes in 
line with the APC-Cdh1 study stressing the role of APC in controlling the G0 state. Other 
genes to be unspecifically regulated are TP53, FAT, PTK7 and CDH11. Those genes 
may help to maintain the G0 state by promoting cell cycle arrest. Importantly, G0 unlike 
senescence, apoptosis or differentiation is not a permanent state but a transitory one, 
therefore it is very likely that oncogenes might help to suppress genes that lead into 
those irreversible states (Coller, Sang et al. 2006). The location of G0 is another point of 
discussion. Experiments in hESCs showed that in early G1 phase differentiation is 
triggered into endoderm, whereas in late G1 were limited to neuroectoderm 
differentiation. Connecting to previous evidence, there seems to be G0-like behavior in 
early G1 (Pauklin and Vallier 2013). 
Together, the evidence shows that understanding precisely where G0 is located, its 
molecular signature and regulation of exit are necessary to understand processes such 
as tumorigenesis, which fundamentally becomes in some cases an active scape from 
G0 states. 
 
5. Molecular events beyond the restriction point 
Exit from G0 is followed by commitment to DNA replication. Once cells cross the 
restriction point, Cdc6 and Cdt1 proteins load the MCM helicase onto the ORC to form 
the pre-RC. To initiate DNA replication CDK and DDK (Dbf4-dependent kinase) activate 
the helicase and load the replisome. “Replication licensing” refers to the process of 
forming the pre-RC. An important safety check during DNA replication is to prevent re-
replication by blocking MCM loading during S, G2 and M phases (Sclafani and Holzen 
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2007). One of the mechanisms of preventing re-replication is the degradation of Cdt1 via 
SCF–Skp2 E3 ubiquitin ligase complex, in which Cdt1 proteolysis is regulated by CDK4 
and CDK2 through phosphorylation favoring the recognition by SCF-SKP2 (Truong and 
Wu 2011). This step also coincides with the inactivation of APC, which has brought 
more recent relevance since it marks the actual point of no return in cell cycle. Cdt1 is 
therefore an interesting marker for the RP as it will be shown in the experiments 
performed in this thesis. 
 
6. Experimental tools used to interrogate cell cycle behavior 
6.1. Cell cycle synchronization methods  
To understand how the molecular machinery that controls cell cycle commitment works 
it is necessary to perform synchronization. That means, arresting cells in a particular 
phase of the cell cycle via physical or chemical methods, and then observe cell cycle 
progression in terms of protein or gene expression levels. This approach has been 
successfully applied to obtain the current understanding of cell cycle regulation in 
different organisms, and in some cases has lead to the discovery of biomarkers for 
cancer prognosis. Of note, synchronization by serum starvation lead to the discovery of 
the restriction point (Pardee 1974). Other synchronization methods such as thymidine 
block, inhibit DNA synthesis and other such as nocodazole inhibit microtubule formation 
arresting cells in mitosis. However, it has been shown that current synchronization 
methods induce serious artifacts that hamper the reliability of certain cell cycle studies. 
Serum starvation has been shown to cause DNA fragmentation and to reduce survival of 
cells. Methods altering DNA replication usually trigger DNA damage response, perturb 
RNA synthesis and induce apoptosis. On top of those artifacts, aligning cells in a 
particular phase does not mean that the molecular machinery remains intact, translation 
and transcription continues in cells that are arrested first so heterogeneity is artificially 
induced in the cells and the levels might not reflect the correct physiological levels 
(Shaw, Payer et al. 2012). This limits the validity of the results. It has been found that 
protein levels of synchronized cells do not correlate with that of unperturbed cells (Gong, 
Traganos et al. 1995) 
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6.2. Genetic reporters for labeling cell cycle phases 
 To address this issue, efforts in developing genetic reporters that facilitates cell cycle 
staging are being developed. The idea in principle is to distinguish cell cycle stages in 
single cells by fluorescence; this allows classifying cells rather than synchronizing them, 
which in addition, gives the power of observing single cell behavior. The most successful 
example were the FUCCI reporters (Sakaue-Sawano, Kurokawa et al. 2008). The 
technique is based on constant expression of Cdt1 (G1 phase) and geminin (S/G2) 
peptides that contain cell cycle dependent degradation signals but lack the active 
domains that could perturb cell cycle in the host cell (Figure 7). The fragments are fused 
to fluorescence proteins (diverse set of panels exist) and the intensity of the signal is 
generally proportional to the length of the cell cycle phase. Interestingly a recent study 
found that the Cdt1 reporter could distinguish G0 cells, those exhibiting the highest Cdt1 
signal exhibited as well Ki-67 negative staining (Tomura, Sakaue-Sawano et al. 2013). 
Given that FUCCI mice exist, the reporter could be a promising alternative to better 
understand the regulation of RP in vivo In the same direction, another reporter was 
develop using a p27-rrdegron (Oki, Nishimura et al. 2014). The probe contained the 
fluorescent protein mVenus and a p27K2 mutant fragment lacking CDK inhibitory activity 
(mVenus-p27K2), which was introduced in NIH3T3 cells. The reporter successfully 
identified the G0 cells and the G0-G1 transition could be observed by combination with 
the other FUCCI reporters. Interestingly, the reporter was active in G1 early and G0 
cells, confirming the findings observed by E2F4 activation in G1 early and low CDK2 
activity reported by Spencer et all. CDK2 activity sensor described above, suggested 
that for cells emerging from a starvation (G0 state), the CDK2low state could be defined 
as a continued G0 state that persists for at least 8 hr after mitogen addition, and the 
initial activation of CDK2 could be interpreted as the beginning of the G1 phase 
(Spencer, Cappell et al. 2013) In addition G1 early cells that had CDK2low remained in 
G0 in normally cycling cells confirming again what was observed using the p27 degron 
reporter. 
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Figure 7. FUCCI reporters used for cell cycle staging. A) Cdt1 and Geminin levels are cell cycle 
dependent and controlled by degradation via SCF or APC complex. B) Diagram of activation of the 
different reporters, Cdt1 predominantly in G1 and early S and Geminin S through Mitosis. (Reproduced 
with the permission of Tatjana Ryl) 
6.3. Methods to extracting cell cycle dynamics from snapshot data. 
The described reporters are useful specially when cells are suitable for live cell imaging. 
But in some cases, some cell lines tend to form clusters or morphology makes difficult 
any attempt of microscopy examination. Cell size is also another factor that hampers 
proper data analysis, specially when the reporters are localized in the nucleus. Another 
interesting approach that is gaining popularity especially in the field of single RNA 
sequencing and Mass cytometry is to be able to extract dynamic data from a static 
picture of a steady state population. Since cell cycle is also a dynamic process with a 
series of defined steps, it becomes a suitable process to be studied using this 
methodology. Usually it involves computing a segmentation of the data, and 
organization of the stages by looking at the intensity of additional markers. Once the 
progression line is established the other markers can be analyzed. However the 
limitations are that cells need to be in steady state and the markers should provide 
sufficient information of all possible transitions. (Kafri, Levy et al. 2013) applied this 
method to determine growth regulation in a population of cells labeled with geminin 
degron and DNA staining. The authors used a mathematical framework called Ergodic 
rate equation (ERA) to extract dynamic information from snapshot data. Using ERA they 
showed that cell-to-cell size variation is regulated by a negative feedback at the G1/S 
transition. The authors also claimed that the dynamics of other processes, such as the 
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temporal changes in phosphoproteins during the cell cycle could be extracted with 
relatively high accuracy . However, in some situations as in the case of cell cycle, the 
snapshot data will exhibit all possible fates taken by the cells, for example, some cells 
will enter S phase and others will arrest in G0 temporarily. These bifurcations are 
evident in the snapshot data since cells are not synchronized. Another method called 
Wishbone went further to address that problem. 
Based on a previously published algorithm from the same group called Wanderlust 
(Bendall, Davis et al. 2014), the authors used nearest-neighbor graphs to capture 
developmental path using using shortest paths. Each node in the graph represents a 
cell, and edges connect each cell to its most similar cells based on expression of the 
markers. Distances between cells can be computed using shortest paths, that is, a 
series of short steps through the neighbors in the graph, where each step between 
closely related cells is likely to represent similarity in degree of maturity. The ordering of 
the cells is refined by using a selected set of cells, called waypoints. The inconsistencies 
in distances between waypoints are used to identify the branch point and branch 
associations for all cells. The algorithm was able to recover the known stages of T-cell 
development in the mouse thymus, including the bifurcation point (Setty, Tadmor et al. 
2016). One last algorithm and the one used here for data analysis is the Difussion maps 
calculation called Diffusion Pseudotime (DPT). The measure is a random-walk-based 
distance that is computed based on simple Euclidian distances in the 'diffusion map 
space'. The diffusion map is a nonlinear method for recovering the low-dimensional 
structure underlying high-dimensional data mid-dimensional data such as FACS. The 
branching is also calculated by comparing pseudotime sequences and measuring the 
correlation, at the point where correlation breaks the branching point is detected (Figure 
8A). The main advantage of DPT with respect to Wishbone is its computationally 
efficiency which comes from using less processing steps which are more susceptible to 
parameter selection, leading to a more robust detection of branching points (Haghverdi, 
Buttner et al. 2016). 
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Figure 8. Diffusion maps method to extract dynamic data from snapshot data.  A) The diffusion 
transition matrix is computed as transition probability from once cell to another (1). Diffusion pseudotime 
dpt(x,y) approximates the distance between cells (2). Branching points are identified as points where 
anticorrelated distances from branch ends become correlated (3) B) Example of dynamics extracted from 
snapshot single cell RNA-seq data. Adapted from (Haghverdi, Buttner et al. 2016) 
7. MYCN effects on cell metabolism. 
As stated previously, MYCN influences predomintantly proliferation, however another 
important process required for cell division is metabolism, and previous studies have 
shown that MYC regulates glucose and glutamine utilization through the increased 
expression of key glycolytic and glutaminolytic enzymes. Increased overall metabolism 
supports cell growth. MYC-high cells use glutamine as carbon source for the 
tricarboxylic acid (TCA) cycle, and deprivation of glutamine was shown to kill cells 
expressing high levels of c-MYC and MYCN (Yuneva, Zamboni et al. 2007, Wise, 
DeBerardinis et al. 2008, Qing, Li et al. 2012) Several pieces of evidence have shown 
that MYC up-regulates enzymes involved in oxidative phosphorylation and similarly to 
RAS it appears to use respiration rather the glycolysis alone for ATP production(Morrish, 
Neretti et al. 2008, Dang 2011, Zirath, Frenzel et al. 2013). Another aspect in close 
connection with cell metabolism is the redox balance which is required for normal 
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cellular functioning (Gorrini, Harris et al. 2013). Oxidative phosphorylation in the 
mitochondria is considered the major intracellular source for ROS, however the final 
cellular response to oxidative ROS depends largely on ROS type, location, and level. 
MYC was previously reported to impact various aspects of redox homeostasis. Despite 
the fact that MYC increases mitochondrial activity and subsequently enhance 
endogenous source of ROS, various antioxidant pathways are also regulated by MYC, 
enabling cells to prevent oxidative damage (DeNicola, Karreth et al. 2011) Recently Lien 
and colleagues found that inhibition of GSH biosynthesis and cotreatment with cisplatin 
can enhance DNA damage therapeutic effect in cells carrying PI(3)K mutation (Lien, 
Lyssiotis et al. 2016). MYC seems to stabilize NRF2 transcription factor, which regulates 
glutamate-cysteine ligase modifier (GCLM) and heme oxygenase 1 (HMOX1) eliminating 
the lethal effects of oxidative stresses (Alam, Stewart et al. 1999, Gorrini, Harris et al. 
2013).  It also has been indicated that c-MYC suppresses ferritin, making the stored iron 
metabolically available for cells, that might sensitize the cells to ferroptosis (Wu, Polack 
et al. 1999, O'Donnell, Yu et al. 2006).  
Ferroptosis is non-apoptotic form of regulated cell death dependent from the 
accumulation of lipid ROS and intracellular iron levels (Dixon, Lemberg et al. 2012). 
Previous work has shown that the activation of ferroptosis is mainly controlled by 
enzymes of GSH pathway, such as SLC7A11and GPX4 (Dixon, Lemberg et al. 2012, 
Yang, SriRamaratnam et al. 2014). Other positive regulators of ferroptosis are p53, 
CARS and NOX (Xie, Hou et al. 2016). Small molecule screen found erastin as potent 
inducer of ferroptosis (Yagoda, von Rechenberg et al. 2007, Dixon, Lemberg et al. 
2012). This molecule was found previously to inhibit oncogenic RAS and GSH 
biosynthesis (Dolma, Lessnick et al. 2003). In vivo experiments using a HT-1080 
fibrosarcoma cells xenograft mourse model showed reduction of tumor growth under 
piperazine-erastin treatment injected subcutaneously (Yang, SriRamaratnam et al. 
2014). Although MYC regulates GSH synthesis at multiple points, to our knowledge 
there are no reports indicating an association between MYC and ferroptosis.  
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8. Aims of the study 
From previous data was concluded that MYCN influences the cell cycle machinery 
leading to uncontrolled proliferation. Reducing MYCN levels promotes G1 phase 
lengthening and it appears to be the same case for other tumor types involving the 
homologous c-MYC. However the mechanism of how MYCN regulates the cell cycle 
machinery to promote proliferation is still not well understood. Regular cell cycle studies 
using chemical synchronization might contain artifacts, which could obscure the real 
dynamics, so we used here cell cycle genetic reporters to study the effects in single 
cells. Metabolic deregulation is another hallmark of oncogenic MYCN and one approach 
to find new potential therapeutical strategies is to explore synthetic lethal combinations 
of metabolic genes with MYCN.  
The aim of the project was to understand how MYCN promotes cell cycle commitment in 
neuroblastoma cells via modulation of the restriction point of the cell cycle. In addition, 
aminoacid metabolism was investigated to find vulnerable points that can be used for 
therapeutic purposes in MYCN-driven tumors. The questions that were addressed in this 
project are the following: 
1. How does MYCN modulate the restriction point in neuroblastoma cells? 
To prevent synchronization artifacts, genetic reporters for cell cycle staging were 
stably integrated in MYCN-amplified cells with tunable MYCN levels. Measurements 
of cell cycle players by FACS and microscopy were performed under different 
perturbations to tease out the role of MYCN in the restriction point.  
2. What are the transcriptional programs driven by MYCN controlling the passage 
through the restriction point? 
 Given the advantage of genetic reporters, cell sorting and transcriptomics can be 
performed in unperturbed cells. This data can give a clearer picture of the effects of 
MYCN on transcriptional program controlling the restriction point. 
3.  Which are the metabolic requirements of MYCN amplified cells? 
Using metabolomics measurements of MYCN amplified cells we intended to detect 
metabolic dependencies specific for high MYCN cells. 
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9. Materials and Methods 
9.1. Materials 
Research equipment 
Microscope Olympus, CKX41    Olympus 
Microscope Olympus, Cell^R    Olympus 
Miltenyi MACSQuant Analyser    Miltenyi 
LSRII        BD Biosciences 
Steri-cult CO2 incubator     Thermo Scientific 
Tecan Infinite M 200     Tecan  
NanoDrop ND-1000 spectrophotometer   NanoDrop 
Vortex Genie       NeoLab 
Thermo water bads      GFL, Hans Byaer, Julabo 
Bioanalyzer        Agilent 
Cell culture hood HERA      Heraeus 
Centrifuges Eppendorf, 
Beckman Coulter 
Qbit        Qubit 
Light Cycler 480      Roche 
FACS sorter Aria II      BD Biosciences 
GC/MS-QP2010 Plus (metabolomics)   Shimadzu® 
 
Molecular biology reagents  
ABSOLUTE qPCR ROX mix    Thermo Scientific 
Agencourt AMPure XP beads    Beckton Dickinson 
Bovine serum albumin (BSA)    Roche Diagnistics  
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Cell Titer Blue      Promega 
ERCC Spike-in control     Life Technologies 
QBit RNA assay       Life TechnologiesMethylene  
PBS        Santa Cruz 
Spike-In       Life technologies 
Real-Time Cell Analyzer (RTCA)    Roche 
 
Kits for molecular biology 
Click-iT EdU Flow Cytometry Assay Kit   Life Technologies 
Effectene Transfection Ragent    Qiagen 
ScriptSeq Complete Gold Kit (Human/Mouse/Rat) Epicenter 
First Strand cDNA Synthesis Kit    Thermo Scientific 
RiboGold Kit       Epicenter 
RNeasy mini Kit       Qiagen 
 
Chemicals and Reagents 
DMSO        AppliChem  
EDTA        Sigma  
Ethanol        Sigma 
Formaldehyde 4%      BioLegend 
FxCycle Violet Stain     Life Technologies 
Vybrant Dye Cycle Violet Stain    Life Technologies 
Isopropanol        Greiner Bio One  
Methanol        Greiner Bio One 
Nuclease-free water     Ambion 
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Triton X-100        Sigma  
RNAse A       Thermo Fischer 
RNAse inhibitor      Clontech 
Monobromobimane       Calbiochem 
Chloroform       Sigma 
Methoxyamine hydrochloride     Sigma 226904 
Pyridine        Sigma  
MSTFA       Sigma 
Table 1 Antibodies and Isotypes for FACS 
Specificity Host Supplier/Catalog 
number 
p-Rb (S807/811) XP Alexa 647 Conjugate Rabbit Cell Signaling/	8974 
SKP2 (D3G5) XP Rabbit Cell Signaling/	2652 
p27 Kip1 (D69C12) XP Rabbit Cell Signaling/	3686 
p21 Waf1/Cip1 (12D1) Rabbit Cell Signaling/ 2947 
E2F1 Rabbit Cell Signaling /3742 
MYCN  [NCM II 100] Mouse Abcam/ ab16898 
p-CDK2 T160 Rabbit Abcam/ ab194868 
mAb IgG Isotype Control Alexa  647 
Conjugate 
Rabbit Cell Signaling/ 2985 
mAb IgG  XP(R) Isotype Control  Rabbit Cell Signaling/3900 
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mAB IgG1, k Isotype Control  Mouse Abcam/ab18443 
Table 2 Taqman® Real-Time PCR Assays 
Gene Assay ID 
MYCN  Hs00232074_m1 
 C-MYC Hs00153408_m1 
CDKN1A Hs00355782_m1 
CDKN1B Hs01597588_m1 
E2F1 Hs00153451_m1 
SKP2 Hs01051864_m1 
CCNA2 Hs00996788_m1 
CCNE1 Hs01026536_m1 
CCND1 Hs00765553_m1 
GAPDH Hs02758991_m1 
UBC Hs00824723_m1 
HMBS Hs00609296_m1 
SDHA Hs00188166_m1 
All TaqMan assays were obtained from ThermoFisher Scientific 
 
Drugs 
LEE011 (CDK4 inhibitor)      Selleckchem 
HLM006474 (E2F inhibitor)     Merck Millipore 
U0126 (MEK inhibitor)      Cell Signaling 
PD0325901 (MEK inhibitor)     Sigma Aldrich 
10058-F4 (MYC inhibitor)      Sigma Aldrich 
Antibiotics for cell culture 
Blasticidin        Sigma 
MYCN modulates the restriction point and ferroptosis in Neuroblastoma [Pick	the	date] 	
28	
Penicillin/Streptomycin      PanReac AppliChem 
G418                 Sigma 
Hygromycin B       Sigma 
Puromycin        BD Clontech 
Zeocin        Invitrogen 
Doxycycline        BD Clontech  
 
Media and supplement for cell culture 
RPMI 1640 (1mM L-Glutamine, 25mM Hepes) Gibco, Life Technolofies 
RPMI 1640 (with L-Glutamine, without Phenol Red) PAA, The Cell Culture 
Company 
Fetal Bovine Serum (FCS) Gibco, Life Technolofies 
Fetal Bovine Serum, dialyzed     ThermoFisher 
 
Plasmids 
The E2F1pr-d2EGFP-pQCXIP construct was kindly provided by Prof. Guang Yao.It 
posses a 800bp fragment of the E2F1 promoter followed by a destabilized form of EGFP 
The plasmids has puromycin resistance. 
pFucci orange G1 was kindly provide by University of Viena. The plasmid has the 
fluorescent protein mKO2 fused to a human part for Cdt1 protein (hCdt1 30-120). It 
degrades at the start of S phase. Resistance is Neo/Kan and the antibiotic used of 
selection is G418. 
The pMOWS_puroR_mCherry_hCdt1 construct was kindly provided by Prof. Ursula 
Klingmüller. It is similar to pFucci orange but instead of mKO2 is tagged to mCherry. 
And the resistance is puromycin. 
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Table 3 Tissue culture cell lines used in the study 
Cell Line Description Reference Selective 
antibiotics 
TET21N 
Derived from SH-EP, 
transgenic inducible MYCN, 
non amplified neuroblastoma 
cell line 
(Lutz, Stohr 
et al. 1996) 
90 µg/ml 
Hygromycin  
200 µg/ml G418  
IMR5/75_shRNA 
MYCN 
MYCN - amplified 
neuroblastoma cell line, 
expresses MYCN shRNA 
under control of tetracycline 
repressor 
(Muth, 
Ghazaryan et 
al. 2010) 
5 µg/ml 
Blasticidin, 45 
µg/ml Zeocin 
TET21N_hCdt1 
Derived from SH-EP, 
transgenic inducible MYCN, 
with recombinant hCdt1 (30-
120) 
Generated in 
collaboration 
with Tatjana 
Ryl 
90 µg/ml 
Hygromycin  
200 µg/ml G418 
7.5 µg/ml 
Puromycin 
IMR5/75_E2F1 
Cdt1 
MYCN - amplified 
neuroblastoma cell line, 
expresses MYCN shRNA 
under control of tetracycline 
repressor, has Cdt1 and 
E2F1 constructs 
Generated in 
the present 
study 
5 µg/ml 
Blasticidin 
45 µg/ml Zeocin 
1 µg/ml 
Puromycin 
200 µg/ml G418 
IMR5/75_E2F1  
MYCN - amplified 
neuroblastoma cell line, 
expresses MYCN shRNA 
under control of tetracycline 
repressor, has E2F1 
constructs 
Generated 
previously in 
the Master 
thesis 
5 µg/ml 
Blasticidin 
45 µg/ml Zeocin 
1 µg/ml 
Puromycin 
 
Software 
Inkscape 
FIJI 
FlowJo X 
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Prism 6 
Matlab 
R 
Bioconductor packages 
STAR 
HTseq 
RSeQC (2.5) 
9.2. Methods 
9.2.1. Cell culture methods 
9.2.1.1. Culturing and cryoconservation of human neuroblastoma cells 
All cells were cultivated in RPMI1640 supplemented with 100 U/ml Penicillin/ 
Streptomycin, and 10% FCS at 37°C, in 5% CO2 atmosphere in a humidified cell culture 
incubator. The cell culture medium was substituted every 3-4 days, and cells were split 
at ration 1:5 when they reached subconfluent density.  Adherent cells were removed 
with a solution of PBS and EDTA. Visual observation of cell morphology was conducted 
under the Zeiss Axiovert microscope, equipped with phase-contrast and bright-field 
optics. The conservation cells were harvested and resuspended in 4 ml of an ice-cold 
cryoconservation medium (RPMI with 40% FCS, 10% DMSO). The cellular suspension 
was dispensed into cryocontainers and incubated at least 24h at -80C prior to deposition 
into a liquid nitrogen tank for long time storage. For recultivation, frozen cells were 
quickly thawed and the cryoconservation medium was substituted with a warm fresh 
growth medium. 
9.2.1.2. Transfection of plasmids and selection of transfected cells 
Transfections were carried out using the Effectene Transfection Reagent. It is a non-
liposomal lipid formulation allowing high transfection efficiency with minimal cytotoxicity. 
Plasmids were transfected into cells, which were seeded 18-24h before transfection. 
Transfection was performed according to manufactural instructions using 1 µg DNA. The 
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transfection medium was replaced by the fresh complete medium 24h post transfection. 
Selection of stably transfected cells was initiated 24h post transfection by addition of 
appropriate antibiotics into the growth medium.  After selection, transfected cells were 
sorted into single cells using fluorescence activated cell sorting to generate clonal 
populations. Individual clones were expanded and analyzed using FACS analysis or 
time-lapse microscopy. 
9.2.1.3. Inhibitors treatment 
Inhibitors HLM006474, U0126, PD0325901, were used 2, 4 and 8 µM concentrations on 
IMR5/75 cells for 24hr. LEE011 was used at 200nM and 10058-F4 at 15 µM. 
 
9.2.1.4. Calculation of growth curves. 
At the appropriate time points cells were dethatched with versene. 1mL of cell-versene 
suspension was collected and 100 µL were counted with the MACSQuant Analyser 
(Milteny) using propidium iodide staining to exclude dead cells. 2x104 cells were seeded 
on RTCA slides for impedance measurements and growth rate calculations. 
 
9.2.2. FACS analysis 
9.2.2.1. Antibody staining  
106 cells were pre-fixed with 4% paraformaldehyde (PFA) for 15 minutes at room 
temperature (RT), then re-suspended in 3ml  ice-cold methanol and incubated overnight 
at -20°C. Cells were then washed in PBS, incubated for 30min in washing buffer 
(1%BSA, 0,1% TritonX in PBS) and stained with fluorescein-conjugated primary 
antibodies for 1 h at RT (Table.2). After washing the cells were stained with FxCycle 
Violet dye for cell cycle analysis.  Data was analyzed with FlowJo software, either Dean-
Jett-Fox or Watson algorithm was used to determine percentage of cell cycle phases. 
Cells with a DNA-content below that of the G1-fraction were considered dead. 
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9.2.2.2. EdU incorporation  
Cells were incubated with 10 µM EdU for 30min prior to collection. 106 cells were fixed, 
permeabilized and stained with the Click-iT Plus EdU Flow cytometry Assays Kit. 
 
9.2.2.3. FACS-Single cell sorting (Cell cycle outgrowth) 
IMR5/75_E2F1 Cdt1 cells were harvested and re-suspended in ice-cold medium. Cell 
sorts were performed using FACS sorter Aria II (BD). For each conditions ~600 or more 
single cells were sorted into 96-well plates according to their cell cycle status. 3 weeks 
after re-seeding, cells were stained with Cell Titer Blue assay, imaged and the number 
of colonized wells counted. Three biological replicates were performed. 
 
9.2.2.4. Live-cell microscopy 
Around 3000 cells were seeded on 8-well Ibidi µ-slides or Lab-Tek chamber slides in 
phenol red-free RPMI 1640 medium and imaged every 10 min for up to 48 hr under 
controlled growth conditions at 37°C, 5% CO2 and 80% humidity. Images were acquired 
with an inverted widefield microscope (Olympus Cell^R) using an CCD Hamamatsu 
Orca-ER camera and a 20x lens (UPlanSApo / 0.75). Bright field images were acquired 
in addition to fluorescence using a light engine lamp. Filters used were EGFP and 
HcRed.  
Cells were tracked manually using FIJI (version 1.48d) (Livak and Schmittgen 2001)  
 
9.2.2.5. Real-time quantitative PCR 
Around 6 × 104 live cells were sorted in PBS with RNAse inhibitor based on E2F1 
intensitiy and DNA content measured with Vybrant Dye Cycle. Total RNA was isolated 
with the RNeasy Mini Kit (Qiagen), following manufacturer’s instructions. Nucleic acids 
were quantified in solution using NanoDrop ND-1000 spectrophotometer by measuring 
absorbance at 260 nm.  
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RNA for the gene expression measurement was reverse transcribed using the RevertAid 
H Minus First Strand cDNA Synthesis Kit (Thermo scientific) according to manufacture 
instructions. Samples to be used in real-time quantitative PCR were diluted with 
nuclease-free water to the final concentration of 2 ng/µL (equivalent of total RNA) and 
stored at -20°C until use. 
DNA was quantified in 384-well format using the LightCycler 480 Real-Time PCR 
System, Table5. For the quantitative gene expression studies, cDNA in the amount of 10 
ng of equivalent of total RNA was used per well. 5 µL of cDNA (2 ng/µL) was mixed with 
6 µL of enzymatic master mix, yielding 11 µL total sample volume. The mRNA level of 
each target gene was normalized to the relative average amount of the internal 
reference genes GAPDH, UBC, SDHA or HMBS. The internal reference genes and the 
target genes were analyzed in parallel for each sample. The relative gene expression 
was calculated using the comparative cycle crossing point (∆∆Cp) method (Livak and 
Schmittgen 2001). 
 
9.2.3. RNA-sequencing  
Around 1 × 105 live cells were sorted in PBS with RNAse inhibitor based on Cdt1 and 
E2F1 intensities and snap frozen in liquid nitrogen. RNA was extracted using Arcturus® 
PicoPure® Frozen RNA Isolation Kit. ERCC Spike-in control mix-1 (Life technologies) 
was added to each sample prior to processing (1 µl of a 1:10 dilution of mix-1). RNA 
from each sample was processed using the RiboGold kit (Epicentre) to remove rRNA. 
The remaining rRNA-depleted sample was then used to prepare libraries for 
sequencing. The RNA library prep kit, ScriptSeq Complete Gold Kit (Epicenter) was 
used for IMR5/75 cells. The Agencourt AMPure XP beads (BeckmanCoulter) were used 
to purify the cDNA. Barcodes for individual samples were added in order to multiplex 6 
samples in each sequencing lane. The qualities of libraries were assessed using a 
DNA1000 chip on a Bioanalyser (Agilent) to ensure the correct size of libraries and the 
concentration was measured using the Qbit DNA assay. Sequencing was performed on 
Illumina platform with HiSeq 2000 Pair-end 100bp sequence type. 
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RNA-Seq reads alignments and counts of raw reads of sequenced IMR5/75 shRNA cells 
were mapped to the human genome hg19 using STAR (2.4.0h1) with default 
parameters. Reads and alignment quality were examined by FastQC (0.10.0) and 
RSeQC (2.5), respectively. Spike-in sequences were concatenated with the hg19 
genome sequence. Read counts were calculated by HTseq via “-s yes”.  
RNA-Seq data were normalized for each sample, the data sequenced in different lanes 
was summated, and read counts of genes were normalized by DESeq2 package in R. 
Normalization size factors were obtained using filtered spike-in raw read counts (≥5 
reads in any sample; “absolute” expression) or filtered whole-genome gene read counts 
(≥10 reads in any sample; “relative” expression). All raw read counts were divided by the 
size factor to obtain a normalized genes expression value used in all further analyses.  
Identification of differentially expressed genes by Likelihood ratio test was implemented 
by the DESeq2 (Love, Huber et al. 2014) package in R used to find differentially 
expressed genes with options “independentFiltering = FALSE, cooksCutoff = FALSE”. 
For differential expression, the maximal absolute fold change between MYCN conditions 
or cell cycle phases had to be ≥ 0.5 and a false discovery rate (FDR) ≤ 0.1. Additional 
analysis were performed using Ingenuity Pathway Analysis suit under the upstream 
regulators option (Kramer, Green et al. 2014). 
 
9.2.4. Quantification of Amino Acids 
Cell pellets of two million cells were extracted with 0.1 ml ice-cold 0.1 M HCl. Non-thiol-
containing amino acids were quantified after specific labeling with the fluorescence dye 
AccQ-TagTM (Waters) as described in (Yang, A et al. 2015). Cysteine was determined 
after labeling with monobromobimane (Calbiochem) as described before ((Wirtz and Hell 
2007). 
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9.2.5. Metabolite Analysis by Gas Chromatography/Mass Spectrometry 
(GC/MS) 
9.2.5.1. Extraction 
We harvested approximately six million cells of MYCN-high and MYCN-low expressing 
IMR5/75, as well as MYCN-high IMR5/75 cells treated with MYC inhibitor (10058-F4), or 
DMSO as control. Intracellular GSH and metabolites of the TCA cycle were analyzed.  
Harvested cells were washed twice with 0.9% ice-cold NaCl solution and immediately 
snap frozen with liquid nitrogen. Frozen pellets were extracted in 180 µl of MeOH for 15 
min at 70°C with vigorous shaking. As internal standard, 5 µl ribitol (0.2 mg/ml) were 
added to each sample. After the addition of 100 µl chloroform, samples were shaken at 
37°C for 5 min. To separate polar and organic phases, 200 µl water was added and 
samples were centrifuged at 11,000× g for 10 min. For the derivatization, 300 µl of the 
polar (upper) phase were transferred to a fresh tube and dried in a speed-vac (vacuum 
concentrator) without heating. 
 
9.2.5.2. Derivatization (Methoximation and Silylation) 
Pellets were re-dissolved in 20 µl methoximation reagent containing 20 mg/ml 
methoxyamine hydrochloride (Sigma 226904) in pyridine (Sigma 270970) and incubated 
for 2 h at 37°C with shaking. For silylation, 32.2 µl N-methyl-N-
(trimethylsilyl)trifluoroacetamide (MSTFA; Sigma M7891) and 2.8 µl Alkane Standard 
Mixture (50 mg/ml C10 – C40; Fluka 68281) were added to each sample. After 
incubation for 30 min at 37°C, samples were transferred to glass vials for GC/MS 
analysis.  
 
9.2.5.3. Gas Chromatography/Mass Spectrometry (GC/MS) Analysis 
A GC/MS-QP2010 Plus (Shimadzu®) fitted with a Zebron ZB 5MS column 
(Phenomenex®; 30 m × 0.25 mm × 0.25 µm) was used for GC/MS analyses. The GC 
was operated with an injection temperature of 230°C and 2 µl sample were injected with 
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split 10 mode. The GC temperature program started with a 1 min. hold at 70°C followed 
by a 6°C/min ramp to 310°C, a 20°C/min ramp to 330°C and a bake-out for 5 min. at 
330°C using helium as carrier gas with constant linear velocity. 
 MS was operated with ion source and interface temperatures of 250°C and a scan 
range (m/z) of 40–1000 with an event time of 0.3 sec. 
The “GCMS solution” software (Shimadzu®) was used for data processing.  
 
9.2.6. Analysis of Intracellular ROS  
Intracellular reactive oxygen species (ROS) levels were measured in approximately 105 
cells using CellROX® (Life technologies). Approximately 105 cells were seeded in 12-
well plates and 24 h later cells were treated with 10058-F4 for an additional day. Cells 
were then fed either with full or cystine-free medium for 24 h. Before ROS being 
analyzed, CellROX was added to the wells at a final concentration of 5 µM and cells 
were incubated in a cell culture incubator for 30 min. After 30 min of staining, cells were 
harvested gently and immediately analyzed by FACSCalibur to measure the signal 
intensity directly proportional to the level of intracellular ROS. 
 
9.2.7. Analysis of Cell Proliferation by (Sulforhodamine B) SRB Assay  
The impact of various medium conditions on cellular proliferation/viability was analyzed 
using SRB assay as described in great detail by (Vichai and Kirtikara 2006). To 
determine changes of cellular proliferation upon incubation with various medium 
conditions, approximately 2 × 104 cells were seeded in full medium in 48-plate format, 
24 h prior to the treatment. Cells were then washed once with PBS and fed with the 
chosen medium. Cell proliferation/viability was analyzed at different incubation time 
points using SRB assay as described in great detail by Vichai and Kirtikara (Vanicha 
Vichai 2006, Nature Protocol). In brief, cells were fixed with ice-cold 10% (trichloroacetic 
acid) TCA for 1 h; fixed cells were then stained with 0.054% w/v SRB for 30 min and 
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absorbance was measured at 535 nm using a Tecan Ultra plate reader (Tecan, 
Maennedorf, Switzerland).  
 
10. Results 
10.1. MYCN promotes cell cycle entry 
10.1.1. Reduction of MYCN leads to prolonged doubling time 
Previous studies have found that MYCN boost proliferation(Meyer and Penn 2008). 
Here we used a tet inducible shMYCN cell line, IMR5/75, that has 75 copies of the 
MYCN oncogene. The reduction of MYCN is not complete (Figure 11A) but significant. 
Through the text, MYCN-low cells will be denoted as the cells were MYCN is reduced by 
the shRNA. There were not reports of doubling times with respect to this particular cell 
line. To get accurate estimates of doubling times, IMR5/75 cells were counted by FACS 
over a period of a week to calculate the growth curve (Figure 9B). This result is 
necessary for further calculations of cell cycle phase lengths that were performed in the 
further sections. To confirm this result, cell growth was additionally measured by 
impedance. IMR5/75 cells either with or without the E2F-d2GFP construct were seeded 
in the RTCA plates.  These device measures electron flow on the surface of the plate. 
Attached cells will interfere with the electron flow generating impedance The higher the 
cell density the higher the impedance, therefore serving as a readout of cell proliferation. 
Impedance in some situations could also indicate changes in cell attachment. Overall 
the results are shown in Figure 9A. The data shows strong accordance between both 
types of measurements as shown in Figure 9C. MYCN-high cells exhibit a doubling time 
of around 16-21 hrs and MYCN-low cells between 35-50 hrs. This clearly indicates that 
reduction of MYCN almost increase by half the length of the cell cycle duration.  
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Figure 9 Growth kinetics of MYCN amplified IMR5/75 cells. A) Impedance measurement of cell growth. 
2 biological duplicates are shown for MYCN-high/low condition. B) Growth curve calculated by counting 
viable cells. SEM is calculated from 3 biological replicates. C) Comparison of doubling times calculated  	
Also interesting to note, MYCN-high cells do not remain viable for longer than 6 days as 
shown in the impedance data (Figure 9A). Perhaps in confluent conditions ROS levels 
are overly toxic for active proliferating cells as shown later in the metabolic section.  
Calculation of the doubling time is mathematical measure that generalizes a value 
based on a population measure. To test if this correlates with the actual growth of the 
cells, MYCN-high cells as an example were sorted in 6-well plates based on G1 DNA 
content and low E2F-d2GFP reporter (Figure 14A). This reporter cell line previously 
generated in the Master thesis will be used here in combination with Cdt1-degron 
marker for characterizing the restriction point in these cells. The results show that after 
50 100 150 200 250
-1
0
1
2
3
4
5
Time (hr)
C
el
l in
de
x
Cell index = A* 2^(t/CI doubling-time)
MYCN-high (1st duplicate)
MYCN-high (2nd duplicate)
MYCN-low (1st duplicate)
MYCN-low (2nd duplicate)
0 24 48 72 96 120
0
2×105
4×105
6×105
8×105
1×106
Time (hr)
(c
el
ls
/m
l)
MYCN-high
MYCN-low 
A B
C
Impedance Growth curve
0
20
40
60
D
ou
bl
in
g 
tim
e 
(h
r)
MYCN-high
MYCN-low 
MYCN modulates the restriction point and ferroptosis in Neuroblastoma [Pick	the	date] 	
39	
15hr cells populate all the phases, seemingly correlated with the doubling time 
calculated based on growth curves and impedance (Figure 10). Interestingly, cells from 
low E2F-d2GFP levels are still able to grow in the MYCN-high condition. This is 
confirmed with further experiments later in this thesis, showing that MYCN-high cells do 
not seem to have a permanent quiescence phenotype. 
	
Figure 10 Cell sorting outgrowth. Left panel: MYCN-high cells sorted by low E2F1 promoter activity in 
G1. Right panel: Measurement of sorted population after 15 hr incubation. 	
In this particular context, it is important that MYCN is the main driver of the observed 
phenotype. However the effects can be masked by its homologous c-MYC. However 
FACS protein staining of c-MYC do not show significant differences upon MYCN 
reduction (Figure 11A: right panel). Therefore it is safe to say that MYCN is the main 
driver of the cell cycle effects observed in this particular cell line. The growth 
measurements showed that MYCN reduction lengthens cell cycle duration by almost a 
factor of 2. To explore if this is can be explained by the proportion of G0 cells, EdU 
incorporation was measured after a 30 min pulse. The results indicate that reduction of 
MYCN increase the proportion of dormant or non-proliferating cells by 10% (Figure 
11C). This is still a modest increase but shows that MYCN might be promoting 
proliferation by inhibiting G1 arrest.  
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10.1.2. MYCN favors crossing of the restriction point 
The Rb-E2F network mostly regulates G1/S transition. The way the mechanism works is 
by deactivating Rb via phosphorylation leading to E2F1 release from the repressing 
complexes and increase of E2F1 expression via auto-activation. To explore if the effects 
observed in the proliferative and dormant fractions are due to changes in the most 
important G1 regulators (Figure 11B), protein staining of pRb807/811 phosphorylation 
site (a marker for cell proliferation) E2F1 total protein and d2GFP we co-stained with 
DNA content staining using FxCycle violet dye. Gates for the cell cycle phases were 
applied using the Dean Jet Fox model in FlowJo. For each of the cell cycle phases, the 
distributions were plotted with either the autofluorescence control or the isotype staining. 
As previously found with EdU incorporation assay, MYCN-low cells accumulate in G1 
with almost 10% more cells. The distributions show some interesting behavior. pRb 
exhibits a bimodal behavior in G1, with almost unchanged levels in the other cell cycle 
phases. MYCN-low cells exhibit a greater accumulation in the negative pRb fraction as 
compared to MYCN-high. This shows that MYCN-high cells do maintain a greater 
proportion of cells in the phosphorylated state, probably the proliferating cells. On the 
other hand, E2F promoter activity (E2F-d2GFP) exhibits a strong shift in G1 with 
moderate shifts in the other phases, favoring usually higher promoter activity levels in 
MYCN-high cells. E2F1 protein levels remain slightly changed in G1 mostly.  
	
Figure 11 Characterization of the cell system. A) Antibody staining shows MYCN reduction upon 
shRNA induction. c-MYC levels remain unchanged. B) pRb807/811 and E2F1 staining together with E2F-
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d2GFP activity for each cell cycle phase. Faded gray distributions indicate either auto-fluorescence control 
or isotype. C) EdU incorporation assay. The gate was calculated with the bifurcate option in FlowJo. 	
Together this indicates that G1 key regulators are strongly affected by MYCN. An 
interesting point is that E2F1 promoter activity did not show a bimodal behavior as 
previously reported by (Yao, Lee et al. 2008). However pRb shows a clear bimodality. 
The relevance of this finding is that its commonly assumed that cell cycle checkpoints 
work as bistable switches exhibiting ultrasensitive behavior, that means if titration of a 
signal is performed, the response curve will look sigmoidal, since low amount of signals 
do not trigger response only until certain threshold is crossed. In single cells measures 
this ultrasensitivity is observed by bimodal distributions that switch from negative to 
positive stats without intermediates. This suggest that the bistable switch might be still 
intact in MYCN-high cells but MYCN might increase the probability of crossing the 
switch evidenced by a higher proportion of pRb positive cells. As for the case of the the 
E2F promoter, perhaps external sources of noise could mask the bimodal behavior, but 
further experiments are required to clarify the noise role in MYC-driven tumors. To 
investigate further the integrity of the bistable switch, we took advantage of normal 
heterogeneity of protein levels in cells. We performed a dose response curve of IMR5/75 
cells stained with MYCN antibody as the signal and then we looked at the E2F-d2GFP 
levels of those cells. The MYCN protein distribution was sliced by intervals of 5%, 
covering all possible MYCN levels using a custom in-house script in FlowJo (Figure 12 
left panel). The median values from the obtained distributions after slicing were 
computed for from the E2F promoter construct and plotted against the median MYCN 
levels as shown in Figure 12 (right panel). The E2F promoter construct values were 
normalized to 1 to allow the behavior to be comparable between MYCN-high and low 
cells. Each point in the dose response curve was mapped to the cell cycle phase using 
the median values for DNA content. Hill equation was fitted to the data using the least 
squares method. Interestingly, MYCN-high cells exhibited hyperbolic behavior, typically 
found in Michaelis-Menten type systems and denoted here by hill coefficient of 1. In 
contrast, MYCN-low cells showed ultransensitive behavior with hill coefficient of 4, 
strongly suggesting the existence of a bistable switch as also evindeced by the bimodal 
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behavior of pRb. Our results suggest that oncogenes might favor crossing of the bistable 
switches by allowing low input signals to engage directly into the high activation state, in 
this case the transition from G1 to S phase. 
 
	
Figure 12 MYCN dose response curve. Left panel: MYCN distributions were sliced by 5% percentiles 
and the intnsity values were plot against E2F-d2GFP values. Middle panel: MYCN-high dose response 
exhibits hyperbolic behavior. Right panel: MYCN-low dose response exhibiting sigmodail behavior.  	
10.2. MYCN drives scape from G0-like state 
10.2.1. Cdt1-degron and E2F1-d2GFP reporters define G1 sub-phases 
This indicates that MYCN-high cells are perhaps more sensitive to growth signals that 
MYCN-low cells. A higher probability to cross the restriction point might be due to 
relatively faster transition or skipping transiently arrested states such as G0. Up to now, 
only few markers are available that could describe the arrested states in a population of 
single cells. For that purpose, the previously generated cell line with the E2F-d2GFP 
promoter construct was transfected with the Cdt1-degron construct which is a marker for 
G1 length. The schematic of the constructs is depicted in Figure 14A. The Cdt1-degron 
construct has a Cdt1 fragment that contains a SKP2 degradation site. An example of a 
microscopic trajectory for Cdt1-degron and E2F-d2GFP dynamics is show in Figure 14B. 
At the beginning of the cell cycle or birth, the cells are colorless but once cells enter in 
G1, Cdt1-degron begins to accumulate. Interestingly, this particular MYCN-low cell 
exhibit higher Cdt1-degron intensity. Previous reports have shown that this might be a 
proxy for G0 arrest. As for the case of E2F-d2GFP, the patterns look similar between 
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MYCN-high and low cells with the difference that MYCN-high cells exhibit a higher 
promoter activity as previously found with the FACS data. 	
	
Figure 13 Reporters Cdt1-degron and E2F-d2GFP used to characterized G1 in neuroblastoma cells. 
A). Schematic representation of the plasmids used. In blue it is indicated the SKP2 recognition site for the 
Cdt1-degron reporter. E2F-d2GFP reporter scheme with c-MYC and E2F1 biding sites. B) Example 
trajectories which each of the reporters. 	
10.2.2. Validation of cell cycle reporters 
Since the description of the initial constructs, no proper validation was carried out at the 
molecular level, for example, correlating promoter activity with mRNA levels or SKP2 
levels vs Cdt1-degron levels. To resolve this issue constructs, we performed live cell 
sorting in E2F-d2GFP cells stained with Vibrant violet dye for live DNA content. 
Populations were sorted by both GFP level and cell cycle phase. Quantitative PCR 
measurements for several genes including E2F1 (Figure 15) revealed that the promoter 
construct reflects the actual gene expression of E2F1 native mRNA (Figure 14A right 
panel). In a similar fashion, the Cdt1-degron anti-correlates with the protein levels of 
SKP2 measured by FACS, as expected by its SKP2 degradation site. Thus, we could 
assume that the reporter constructs are good proxies for E2F1 mRNA and SKP2 
activity. 
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Figure 14 Validation of the reporters. A). E2F-d2GFP vs DNA content plot used to sort populations for 
qPCR measurements. Middle panel: Shows relative mRNA levels from the sorted populations for E2F1 
gene in MYCN-high cells as an example. B) Co-staining of SKP2 and Cdt1-degron showing anti-
correlation. 
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Figure 15 qPCR measurements of additional mRNAs involved in cell cycle regulation. Here is 
shown in blue the MYCN-low cells and in red MYCN-high cells. The data comes from the previously E2F 
vs DNA sorted cells. (Data generated in collaboration with Tatjana Ryl) 
The sorting approach based on cell cycle markers turned to be a valuable tool for 
evaluating the expression genes in a cell cycle dependent manner. This prototype 
experiment helped to develop the sorting-RNAseq protocol employed in this thesis. This 
initial mRNA measurements from sorted cells exhibited interesting patterns. As expected 
Cyclin A2 rise up in S phase opposite to p21 levels, as expected for normal proliferating 
cells. Interestingly for SKP2, MYCN-high cells exhibit a constant increase in the levels 
contrary to MYCN-low cells where it only increased in S phase. Cyclin E is another 
textbook example where only expression was observed in G1. Cyclin D1 seems more 
counterintuitive since the levels are reduced in MYCN-high cells but higher in MYCN-low 
cells. These results might suggest that Cyclin D1 might not be crucial for proliferation in 
this particular cell type. 
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10.2.3. MYCN reduction leads to increased Cdt1-degron levels 
The single cell trace showed in Figure 13 for MYCN-low showed an increased in Cdt1-
degron levels. Additional cells (7 for each condition) were manually tracked and the 
levels for Cdt1-degron are visualized in Figure 16. A heatmap was created based on 
intensity levels as shown in the example of Figure 16 (right panel). The first 7 cells are 
MYCN-high and the remaining ones MYCN-low. 
	
Figure 16 Heatmap representation of Cdt1-degron microscopy trajectories. Left panel: First 7 cells 
are MYCN-high and the others are MYCN-low cells. Right panel: Representation of the color scheme 
used on the trajectory to draw the heatmap. 	
The overall trend is that MYCN-low cells seem to have higher amounts of Cdt1 and 
therefore longer G1 lengths. The accumulation of Cdt1-degron is interesting as it might 
indicate that SKP2 function is affected as also shown with the mRNA measurements 
from sorted cells. However, manual tracking of cells is tedious in IMR5/75 cells since 
they tend to form clusters, therefore selecting cell boundaries becomes extremely 
difficult. Future experiments involving CYTOO chips with micro patterns will be an 
interesting alternative to generate microscopy trajectories and follow progenies in 
IMR5/75 cells. Even though the sample is small, some cells seem to have additional 
interesting behaviors. Cell 10 for example has a long cell cycle but fails to increase Cdt1 
levels. Cell 1 has as well a long cell cycle as well and classified as MYCN-high but did 
not increase Cdt1 as well. Even though the heatmap visualization is informative, certain 
patterns might be not clearly visualized due to the different lengths of the trajectories. 
One option is to align the trajectories to the universal time. The universal time is 
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computed as the geodesic distance between two points in the trajectory and calculates 
the velocity on them. This adjust the “normal” time correcting for shifts and aligning 
trajectories to identify patterns. As shown in Figure 17, the computed trajectories are 
then aligned in the Universal time axis. As expected Cdt1-degron signals increased 
mostly at the beginning as expected for being a G1 marker. E2F-d2GFP starts in later 
time points and rise up (around 0.5 Universal time) when most of Cdt1-degron signals 
are stating to drop. An interesting observation is that MYCN-low signals as observed in 
the previous heatmap do increase in intensity as compared to MYCN-high signals. 
	
Figure 17 Universal time calculation  on microscopy trajectories. (Analysis performed in collaboration 
with Laleh Haghverdi). 	
However as for the case of E2F-GFP in MYCN-low cells the behavior reveals some 
interesting features. It does seem as if E2F1 promoter activity has a relatively small 
increase, which later stabilizes for the case of MYCN-low cells but for the MYCN-high 
cells continues in increase. This suggest that perhaps MYCN-low cells enter cell cycle 
with the machinery necessary to enter commitment and perhaps make an attempt to 
enter into cell cycle but additional factors promotes delay leading to reduction again of 
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E2F promoter activity concomitantly with a continue increase of Cdt1-degron. This is 
later fixed by a newly increase in E2F promoter activity. Another interesting point is that 
the decision appears to be very fast at the beginning of the cell cycle since MYCN-high 
cells do not continue increasing Cdt1-degron. This might suggest than an early activity 
of SKP2 is necessary for degrading inhibitors that might halt cells in the cell cycle. 
 
10.2.4. G0-like state is identified by combination of Cdt1-degron and 
E2F-d2GFP reporters 
Since the number of microscopy trajectories is limited, the further experiments were 
focused on single cell data in the context of the whole population such as data obtained 
by FACS. Initial measurements of E2F-d2GFP vs Cdt1-degron in 3 biological replicates 
revealed a strong difference in MYCN-low cells (Figure 18). In this experiment, cells 
were gated in G1 using DNA content and the gating approach applied previously. The 
data shows that cell cycle starts with low Cdt1 and E2F as shown previously in the 
microscopy trajectories. There seem to be an increase in both signals as cells progress 
in G1 with a decrese in E2F promoter activity followed by a continuous increase in Cdt1-
degron level. This last population seems to appear in both MYCN-high and MYCN-low 
cells. Interestingly, cells in MYCN-low condition tend to accumulate strongly in this 
region. This finding strongly correlates with the high Cdt1-degron levels observed in 
microscopy trajectories in MYCN-low cells.   
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Figure 18 E2F-d2GFP vs Cdt1-degron measurements by FACS. The results indicate 3 different 
biological replicates in MYCN-high/low condition. 	
To evaluate if there was a significant difference in the G1 populations, we applied a 
Expectation-Maximization (EM) algorithm to the gate samples. In this analysis all cells 
were included and not exclusively G1. This method was implemented in the package 
Wanderlust (Bendall, Davis et al. 2014) and runs in the Matlab platform. The gating 
(clustering) method is an iterative algorithm that attempts to find the maximum likelihood 
of a gaussian mixture model. The clustering algorithm was applied with different number 
of expected populations (up to 10). Interestingly the algorithm converged to 4 specific 
populations as shown in Figure 19B. This correlates with the density probability 
estimation shown by the contours in Figure 19A. To facilitate the reference to this 
populations, some arbitrary names were given such as G1 early for the initial Cdt1-
degron and E2F promoter activity boost, the more steady increase named G1 late, the 
strong E2F promoter levels and Cdt1-degron negative population as S/G2 and the 
population with extreme high Cdt1-degron levels and negative E2F promoter activity as 
G0-like. The names are giving based on the temporal pattern observed in microscopy, 
however it is important to mention that the names in this data do not attribute any 
temporal properties since it is a snapshot measurement on a steady state population. 
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The G0-like term was coined from the previous work from (Spencer, Cappell et al. 
2013). In the study, G0-like referred to the state where cells transiently arrest before 
resuming entry into cell cycle, which seems to be the case after MYCN reduction.  
 
 
Figure 19 Definition of the populations in G1. A) Probability density plot of MYCN-high/low cells. B) 
Calculation of gates using the EM algorithm (see text for details). C) Proportion of cells calculated from the 
gating strategy. 	
10.2.5. G0-like state is transient and reversible 
Proportions of the gated populations detected by the algorithm demonstrate that the G0-
like population is significantly higher in MYCN-low as observed previously by visual 
inspection. Interestingly it seems that cells in G1 early also strongly accumulate in 
MYCN-low cells, being only G1 late and S/G2 the populations were MYCN-high cells 
accumulate. This indicates that after MYCN reduction cells might enter a transient state 
probably due to lack of mitogenic signals which is perhaps solved after a certain specific 
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amount of time. To test if the G0-like state was really a transient state, again analysies 
of the microscopy trajectories were performed. The rate of change of Cdt1-degron and 
E2F promoter activity was measured and plot it using the quiver function in matlab as 
shown in Figure 20. The arrows indicate the velocity of the particular point and the 
direction that the trajectory takes in the space. Contour plots were drawn to illustrate the 
areas where high density of points were observed, this with the purpose of detecting 
arrested transient states. Interestingly, the traces indicate that MYCN-low cells and 
perhaps some MYCN-high cells do reduce velocity of progression in the area defined as 
G0-like state. After certain amount of time cells seem to resume cell cycle by increase in 
E2F promoter activity and degradation of the Cdt1-degron.	
	
Figure 20. Microscopy trajectories represented as velocity vectors. The derivatives of each time point 
were calculated with the size of the arrow representing the velocity and the contour plot the density of time 
points. 	
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Therefore it is a safe assumption to catalogue the G0-like cells as transient state where 
cells slow down in cell cycle progression but that eventually is resumed leading to cell 
cycle division. It is possible that since the microscopy trajectories are limited some cells 
might be arrested for longer or permanently arrested not being able to generate 
proliferating progeny. To test for this, cells were sorted from the S/G2 and G0-like 
populations into 96 well plates and let grow for around 3 weeks. Colonies were counted 
by microscopic inspection and the average number is show in Figure 21. The S/G2 
population was used as control of proliferating cells and G0-like cells to test for the 
ability to produce colonies. Other populations could be sorted, such as the G1 early and 
G1 late however the growth profiles of these populations could give somewhat mixed 
results since probably there is where the entry in G0-like is decided. Future experiments 
should be done to test these 2 additional populations. 
	
Figure 21 Cell sorting outgrowth from S/G2 and G0-like populations. Left panel: Average number of 
colonies counted for all conditions. Right panel: Microscopy pictures of some example colonies. 	
Colony counting shows (Figure 21 left panel) that G0-like cells are capable of generating 
colonies either in MYCN-high or low condition. Interestingly enough the colonies 
generated by the G0-like cells coming from MYCN-high cells are larger in number. This 
could indicate that MYCN-high cells in G0-like state have some “advantage” that allows 
faster proliferation, perhaps the levels of MYCN itself. S/G2 colonies are still lower in 
MYCN-low cells but this might due to some cells from that population entering the G0-
like state. An aspect that might also play a role is the inheritance from the previous cell 
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cycle could also explain why the G0-like state cells either with MYCN or not do not 
repopulate at the same proportion as the S/G2 cells. However to strongly verify ths point 
which is in theory interesting, is to collect more microscopy trajectories and perform 
lineage analysis. 
One of the advantages of the snapshot data is that gives an overview of the cells in the 
whole population and allows to identify small subpopulations that might be missed by 
averaging the population or not enough single cell throughput for microscopy 
trajectories. However the disadvantage is that the dynamics or temporal information will 
be missing. Early mathematical analysis (Watanabe and Okada 1967) has shown that 
under certain conditions such as ensuring exponential transitions among the states one 
could infer temporal properties of the data. For example based on steady state data 
such as DNA content proportions and using the doubling time one could simply estimate 
the time spent in each of the phases, but it is not a simple proportion since the model 
takes into account the effects of doubling the population after each division and cell loss. 
The original model was used for G1, S and G/M populations but here instead we used 
the proportions discovered by the clustering analysis on the E2F-d2GFP vs Cdt1-degron 
FACS data. We assumed that populations are in constant transit among states and that 
cell loss is relatively constant. The results are shown in Figure 22A: 
	
Figure 22 Calculation of G1 and G0-like length. A) Steel formulas were used to calculate the G1, G0-
like and S/G2 length based on the proportions determined in Figure 19 and doubling time calculated in 
Figure 9. B) G1 and S/G2 length calculated from microscopy trajectories. 	
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10.2.6. G0-like state can be induced by mitogen starvation  
The calculations revealed that G0-like state in MYCN-low cells could last approximately 
20 hrs, which is almost one cell cycle. However G1 (composed here by G1 early and 
Late) also accounts for an important part of the cell cycle lengthening of around 16 hrs. 
This could be explained by the accumulation of cells in G1 early as observed in the 
proportions in Figure 19B. Interestingly G0-like length in MYCN-high cells is very short, 
of around 5 hrs. This might explain why MYCN-high cells could generate potentially 
more colonies in the MYCN-high condition.  
Together this indicates that cells with high MYCN enter cell cycle faster via skipping the 
G0-like state. This is tightly connected to the restriction point of the cell cycle. Cells in 
the mitogen sensitive window respond by increasing E2F levels until the point that the 
transition becomes irreversible without the need of mitogens. If cells lack enough 
mitogen signals they enter the quiescence state. The definition of quiescence is 
somewhat arbitrary as in some cases might indicate a more permanent state. However 
to test if the G0-like state defined previously is related to the quiescence or G0 state, we 
performed serum deprivation of the G1-gated IMR5/75 cells and analyzed the behavior 
of the E2F promoter and Cdt1-degron reporters as shown in Figure 23.  
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Figure 23 Serum starvation of MYCN-high/low cells. The data represents the increase in G0-like state 
proportions after complete serum starvation for 24 hr. 	
Interestingly, the cells indeed accumulated in the G0-like state after 24 hrs of serum 
deprivation independently of the status of MYCN. Around 20% more were arrested in 
G0-like for the MYCN-high condition and almost 10% more for the MYCN-low case. 
However the treatment also strongly affected G1 early and late E2F promoter activity. 
This shows that a stronger effect in the mitogen signal abrogates even the intial E2F 
boost in G1 early and late. This effect is more pronounced in the MYCN-low situation. 
Perhaps one mechanism that could explain the data is defining the G0-like state as an 
endpoint phenotype where cells arrive after not fulfilling the requirements for cell 
division, but in some cases like in the reduction of MYCN, cells can still enter the G0-like 
state after making fail attempt with an initial E2F boost.  
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10.2.7. G0-like state is unresponsive to p21 and p27 knockdown  
Among the regulators of G0 are the cell cycle inhibitors p21 and p27. Especially p27 
acts by inhibiting CDK2 and promoting cell cycle arrest (Sherr 1996). On the other hand 
p21 seems to be involved in cell cycle arrest after DNA damage (Gartel, Ye et al. 2001). 
However the quiescence CDK2 reporter study (Spencer, Cappell et al. 2013) showed 
that cells could still be arrested in G0-like via specifically p21 induction. To evaluate if 
either p21 or p27 are involved in the regulation or maintenance of the G0-like state, 
siRNA inhibition was performed by liposomal transfection with different siRNA doses. 
The results for 10µM treatment are shown in Figure 24. 
 
	
Figure 24 siRNA knockdown of p21 and p27 in MYCN-high/lowc cells. Control cells represent cells 
treated with lipofectamine. Scrambled are cells treated with unspecific siRNAs. The p21 and p27 siRNAs 
were used at a concentration of 10 µM for 48 hrs.  	
Surprisingly p21 and p27 inhibition did not influence the proportion of cells in the G0-like 
state. This come as surprise since those are the classical inhibitors associated with the 
G0 phenotype. However one possibility is that some cells might not require the same set 
of inhibitors to control cell cycle regulation as pointed out in (Spencer, Cappell et al. 
2013). To test if p57, which is a stronger inhibitor of cell cycle (Matsuoka, Edwards et al. 
1995), was involved, we performed protein staining in IMR5/75 cells and p57 
distributions were gated by cell cycle phase (Figure 25).  
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Figure 25 p57 stainings of MYCN-high/low cells.  
p57 levels remained unchanged in all cell cycle phases and independently of MYCN 
status. The results indicate that there might other potential regulators of the G0-like 
state, which do not necessarily involve the classical cell cycle inhibitors.  
 
10.2.8. G0-like state can be identified in other cell systems  
Together, the data shows that the system Cdt1-degron and E2F-d2GFP in combination 
allows a very complete description of all cell cycle phases and G1 sub phases present in 
in amplified neuroblastoma cells. The novelty relies on the ability to detect the G0-like 
state, which is strongly affected by MYCN reduction. Serum starvation experiments 
indicate that the G0-like state is driven by mitogen signaling which strongly suggests 
that the system developed here allows accurate monitoring of the transition through the 
restriction point. However it is useful to validate the system in other cell types to confirm 
if the G0-like state can still be detected independently of the cell system. To accomplish 
that task, the reporters were also transfected into HeLA cell line. This particular cell 
system is interesting since Rb and p53 are inactivated by the papilloma virus infection 
(Giacinti and Giordano 2006). This explains the fast growth rate of this cell line. The data 
from all cell cycle phases is shown in Figure 26. As expected, the cells do exhibit 
increase in E2F promoter activity and Cdt1-degron levels, but there is complete absence 
of the G0-like state as confirmed by the measurements in two different clones. This 
could be an indication of the absence of active Rb, which impedes cell cycle arrest. 
10
1
10
2
10
3
10
4
0
20
40
60
80
100
%
 C
el
ls
10
1
10
2
10
3
10
4
p57 (log10 a.u)
10
1
10
2
10
3
10
4
G1/G0 S G2
MYCN modulates the restriction point and ferroptosis in Neuroblastoma [Pick	the	date] 	
58	
Additionally p53 might also play a role, since p21 might not be expressed or remain in 
low levels.  
	
Figure 26 E2F-d2GFP and Cdt1-degron data in HeLa cells. Two different single cell clones were used 
for comparison 	
As shown in Figure 11B, Rb phosphorylation correlates with E2F promoter activity in G1. 
This becomes useful as different cell lines with construct might have antibiotic resistance 
that could To evaluate if the G0-like state can be detected in another neuroblastoma cell 
line with no MYCN amplification, the Tet21N cell line was used that carries an inducible 
MYCN system. As comparison, IMR5/75 Cdt1-degron only were also co-stained with the 
pRb807/811 antibody. Indeed, the G0-like appeared evident in this combination of 
markers. Tet21N cells exhibited a higher number of G0-like cells compared to IMR5/75 
which could be caused by the sensitivity of this cell line to cell-contact arrest. 
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Figure 27 Detection of G0-like state in Tet21N cells. Upper panel: IMR5/75 cells with Cdt1-degron only 
construct co-stained with pRb807/811. Lower panel: Tet21N cells with same co-staining as IMR5/75 cells. 	
10.3. Cell cycle regulators promote commitment at G1 early under high 
levels of MYCN  
10.3.1. SKP2 and pRb levels are reset after cell division more strongly 
in MYC-low cells 
These results clearly show that the Cdt1-degron in combination with E2F1 promoter or 
pRb staining could distinguish the G0-like in other cell systems. Further experiments 
could include the optimization of the reporters with brighter fluorescent proteins more 
suitable for microscopy. Of note, the G0-like state when using the pRb staining shows a 
separation on pRb levels already from the start of the cell cycle. This is an interesting 
question since it is not known where exactly in G1 that MYCN exerts its proliferative 
effects. It is probable that MYCN might modulate other cell cycle regulators favoring cell 
cycle entry and scape from the G0-like state, which could happen either in G1 early or 
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potentially in G2/M. To address this question other regulators of cell cycle were co-
stained with the Cdt1-degron and E2F promoter system. The co-staining was performed 
in different samples, meaning that each sample with Cdt1-degron, E2F-d2GFP and DNA 
content was co-stained with an additional protein. This is a limitation and relies in the 
difficulty of co-staining several proteins on the same cell when lacking antibodies labeled 
with spectral compatible characteristics. Additionally when using secondary antibodies, 
species of origin impose a problem since many antibodies are produced usually from 
mouse or rabbit. However, by using the cell cycle markers as common frame one could 
in principle compare patterns among different samples preserving some validity since 
the patters are highly reproducible. One important aspect is to make sure that cells are 
always in the exponential phase. The results of the stainings are shown in Figure 28: 
	
Figure 28 Localization of regulators of cell cycle in the E2F-d2GFP vs Cdt1-degron plot. A) protein 
stainings were gated by 5% highest intensity population (positive cells) and highlighted on E2F-d2GFP vs 
Cdt1-degron plot. B) G2M/G1G0 ratio of the different regulators. 	
The E2F-d2GFP and Cdt1-degron axis is displayed for each of the proteins. To locate 
where each of the proteins is located in the cell cycle axis, the histograms were 
segmented by the 5% of the positive populations. This ensures that only positive cells 
for a particular marker are chosen. The positive cells then are highlighted to find in 
which cell cycle phase they are clustered. The patterns show some interesting 
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characteristics. EdU labeling used here as control, shows that active proliferating cells 
are clustered on the top where the S/G2 region is located and part of the G1 late region. 
As for pRb, it shows correspondence with EdU staining however active pRb seems to 
reach the region for G1 early as well. E2F1 protein clusters in the area similarly 
populated by pRb but in addition seems to be present in the G0-like state. SKP2 on the 
other hand it is only present in G1 early. For the case of the inhibitors (p21 and p27) 
they cluster in the G0-like region. However, as shown previously in Figure 24, siRNA 
knockdown of these inhibitors did not affect significantly the G0-like proportion of cells. 
pCDK2 which is a marker for active CDK2 and therefore proliferative cells, shows 
surprisingly clustering in the G0-like area. Lastly, MYCN seems to be populating G1 
early region in similar way as SKP2, one of its direct targets. This might suggest that 
MYCN might prepare cells already in G1 early rather than in G2. Interestingly, G0-like 
cells do also exhibit accumulation of MYCN, this also comes as surprise since one 
logical assumption was that G0-like cells could enter this state due to lack of MYCN. 
Overall, the patterns of the regulators do match with the expected behavior with some 
interesting exceptions. However there is no an evident difference in patterns regarding 
to MYCN levels, by simple inspection MYCN-high and low cells do behave similarly. 
However it is interesting to note that MYCN, pRb and SKP2 levels are higher in G1 early 
and nearly absent in S/G2. This suggest that the point of commitment might start 
already very early after birth. To evaluate if G2/M levels could dictate the fate in the 
following cell cycle, we calculated the median levels of the proteins in G2/M and dividing 
these values by the ones calculated in G1. In theory, most of proteins if there is no 
active degradation or dephosphorylation, they should half after division. For example, 
DNA content is 4N in Mitosis and once cells divide the daughter cells should inherit 2N 
DNA content. A perfect G2M/G10 ratio would agree with this phenomenon. The results 
are shown in Figure 28B. As expected, EdU ratio is a perfect 2 and it is identical for 
MYCN-high or low cells. Interestingly p21 and p27 do not seem to change from the 
moment of division and the next cell cycle. Strikingly SKP2 and pRb change dramatically 
in MYCN-low cells indicated here by the ratios of 8 and 6 respectively.  
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10.3.2. pRb is phosphorylated in MYCN-high cells at the moment of 
birth  
To investigate what is the reason for the high G2M/G10 ratios, the same procedure used 
to calculate the MYCN dose response curve was applied here to slice the Cdt1 
distribution by 5% percentile and look at the distributions of the regulators: pRb, SKP2 
and as controls E2F1 protein and p21.  As shown in Figure 29, some interesting 
changes are observed at the moment of birth. In the top left corner, the pRb distributions 
show distinct behaviors during G1 with respect to MYCN levels. MYCN-low cells (on the 
right) exhibit a bimodal behavior with pronounced amount of pRb negative cells. The 
behavior does not change through G1 progression and in the G0-like region (last 7 
slices) cells do completely arrest with low pRb levels. As for the case of MYCN-high 
cells, the cells are mostly shifted to the positive pRb mode, indicating that MYCN-high 
cells are already committed to cell cycle at the moment of birth. SKP2 also exhibits a 
similar trend, although less pronounced than pRb, SKP2 seems to be shifted to high 
levels in MYCN-high context and slightly more SKP2 negative cells in the MYCN-low 
case. 
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Figure 29  Cdt1 slices and distributions of important cell cycle regulators. Cdt1-degron plot was 
sliced by 5% percentiles and the distributions for pRb, SKP2, E2F1 and p21 are shown 	
The S and G2 levels of both pRb and SKP2 remain very similar in MYCN-high and low 
conditions, so the reason of the change in G2M/G10 ratio might be related to the strong 
differences in G1 early at the moment of birth. E2F1 and p21 do not show evident 
changes at the moment of birth, although there is a slight increase in E2F1 positive cells 
in MYCN-high condition and slightly higher variance in p21 levels. This gives additional 
evidence excluding the role p21 in driving the G0-like phenotype after MYCN reduction 
opposed to what it was previously found by (Spencer, Cappell et al. 2013). It is also 
important to clarify that the levels at S/G2 phases are coming from cells that enter cell 
cycle, perhaps recovering from the passage through the G0-like state. This suggests 
that during G1 there might be 2 populations of cells that share an initial trajectory but 
then it bifurcates into a branch that goes further in S and G2 phases and the remaining 
branch entering the G0-like state. 
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Thus, the slicing approach suggest two main findings: 1) pRb and SKP2 are strongly 
affected in G1 early and this could be the responsible for the cell fate, 2) p21 does not 
seem to play an important role in the initial commitment. 
 
10.4. Diffusion maps analysis to extract dynamics from snapshot data 
10.4.1. Diffusion maps detect a bifurcation in G1 early  
The disadvantage of the slicing approach is that it only allows for a visual inspection of 
the potential changes in the distributions. Therefore a more rigorous mathematical 
analysis is needed to accurately determine potential bifurcation points, and perhaps infer 
dynamics from the snapshot data to detect significant changes in the progression of the 
reporters. As stated earlier in the introduction, dynamics from snapshot data can be 
extracted under certain assumptions such constant flow among populations with 
negligible loss rate. To accomplish that task, the Diffusion pseudotime algorithm was 
used (Haghverdi, Buttner et al. 2016). The previously generated data for each of the cell 
cycle regulators was used (except EdU data). Around 1000 cells were used for the 
analysis, and data was log-transformed for the fluorescence channels while leaving the 
scatters (side and forward) and DNA content as linear. For this type of analysis the main 
goal is to include as many markers as possible, however as explained above, the 
stainings were performed 1 per sample separately. To solve that issue, metacells were 
constructed. The process consists in aligning cells via common markers such as Cdt1-
degron and E2F-d2GFP and then proceeds to add all the other markers to create a 
dataset as if one sample was measured. This procedure allows a more accurate 
comparison of the markers regarding one particular common axis. Technically, for 
creating the metacells, we first chose a reference data file, in this case the isotype 
control which only has the cell cycle markers and no protein stainings. For 1000 
randomly chosen cell in the reference file, 3 nearest neighbors were found in the 
remaining 7 data files using the shared markers (FSC, SSC, Cdt1-degron, E2F-d2GFP, 
DNA content). The value of the additional protein from each file was taken from those 
neighboring cells, resulting in n*3 total metacells, each with 5+7 feature measurements. 
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Once the metacells are created, the starting cell is set from the Cdt1-degron and E2F1-
d2GFP plot and then diffusion map calculation follows. The algorithm detects the most 
likely trajectory the potential bifurcation points. The data can be interpreted as a 
principal component analysis (PCA) plot where the different markers contribute to the 
direction of the trajectory. In the Figure 30, both diffusion maps are plot it for the MYCN-
high and low conditions. The map is color coded by the DNA content to indicate the 
direction of the cell cycle progression. 
	
Figure 30 Diffusion maps of metacells constructed from all the different cell cycle regulators. Right 
panel: Branching point is illustrated in MYCN-low as an example. Color scale is based on DNA content. 
(Analysis performed in collaboration with Laleh Haghverdi). 	
The direction of progression starts with the blue area indicating G1 and goes further into 
the highest DNA content (depicted in red) to the G2/M phase. Interestingly, the diffusion 
maps exhibit bifurcation at early stage in the progression. The bifurcation is more 
pronounced in MYCN-low as expected due to the higher density of G0-like population. 
MYCN-high cells still exhibit a represents the G0-like state. The unbiased detection of 
the bifurcation point predicts that in fact the entrance into G0-like state might be already 
defined in G1 early. This confirms the previous assumption based on robust 
mathematical analysis. Once the diffusion map is calculated, the trajectories for the 
other proteins can be plot it with respect to the diffusion pseudotime (DPT), which is a 
random-walk-based distance that is computed based on simple Euclidian distances in 
the 'diffusion map space'. This measure gives the sense of dynamics of the snapshot 
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data. As stated earlier, this computational method could provide useful information that 
is otherwise impossible to obtain experimentally without incurring in artifacts, specially 
the ones caused by cell cycle synchronization. To confirm the validity of the DPT 
calculation we first check if the dynamics predicted by DPT reflects the biological set up, 
we performed plots of the E2F1-d2GFP and Cdt1-degron markers by color coding DPT. 
Smoothing of the data was performed to obtain the average trajectory. The results in 
Figure 31 show strong resemblance to the trajectories obtained from microscopy (See 
Figure 20).  
 
10.4.2. Dynamics extracted from snapshot data correlates with 
microscopy data 
From the dynamical point of view, the analysis also shows that MYCN-low cells spend 
more time in the G0-like state, which can easily be visualized by looking at DPT values 
of the trajectory that moves towards the S/G2 area. In MYCN-low cells, this area 
corresponds to 2000 value of DPT and in MYCN-high to the 1500 DPT value. Another 
interesting observation is the difference in the slope of the trajectory at the start of the 
cell cycle. MYCN-high cells do exhibit a steep increase in E2F1-d2GFP values 
compared to MYCN-low cells. This pattern was previously discussed with the analysis of 
microscopy trajectories and some trajectories show that cells could generate a fail 
attempt to increase E2F1 promoter activity and the withdraw from cell cycle entering the 
G0-like state. However the average trajectory calculated here only indicates that there is 
not significant increase in E2F promoter activity but only slow accumulation of Cdt1-
degron until reaching the G0-like levels. More microscopy trajectories are needed to 
clarify this point at the single cell dynamics. However it is safe to assume that the 
trajectories draw from snapshot data is a good representation of the dynamical 
properties of the system as confirmed with the few microscopy trajectories.  
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Figure 31 E2F-d2GFP and Cdt1-degron trajectories from snapshot data calculated with DPT. Color 
scale represents the diffusion pseudotime. (Analysis performed in collaboration with Laleh Haghverdi). 	
10.4.3. Dynamical analysis revealed E2F1 as an early regulator of cell 
commitment  
Since the algorithm could successfully reproduce the dynamical behavior observed by 
the cell cycle markrs, it becomes more interesting to evaluate the dynamics of the other 
protein markers. For that purpose, the protein dynamics extracted from the DPT analysis 
were plotted as heatmap with prior normalization of the values from 0-1 to render the 
intensities comparable. The results are shown in Figure 32. 
	
Figure 32 Trajectories of other cell cycle regulators with respect to DPT. Color scale represents 
normalized intensity of the regulators. (Analysis performed in collaboration with Laleh Haghverdi). 	
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As previously shown with the microscopy data, the Cdt1-degron reporter marks the G1 
length. The intensity falls at around 1600 for MYCN-high cells and 2000 for MYCN-low 
cells. This confirms again the longer G1 length of MYCN-low condition. E2F promoter 
activity increases after the drop in Cdt1-degron levels and it is mimicked by the DNA 
content in both conditions. MYCN itself does not seem to increase comparatively in both 
conditions but only at the end of the cell cycle. E2F1 protein, on the other hand, 
increases earlier in MYCN-high cells reaching the maximum at around 1000 DPT as 
compared to 1500 in MYCN-low cells. The other regulators do not seem to differ 
strongly in the dynamics; only pCDK2 seems to be the highest in G2/M mimicking 
MYCN levels. pRb and SKP2 did not appeared in this analysis as predominantly up-
regulated in G1 early as compared to the slicing analysis. One reason for the 
discrepancy is intensity normalization was performed to compare all the markers and 
that could mask the initial boost of some markers. So it is suggested that combination of 
different analysis is a better alternative for making conclusions of the mechanism. 
 
10.5. Mitogenic signaling cooperates with MYCN to favor cell cycle 
commitment in G1 early 
10.5.1. Common growth factors do not induce proliferation in 
Neuroblastoma cells 
In summary the data suggests that pRb, SKP2 and E2F1 levels are strongly affected in 
G1 early as revealed by slicing analysis and DPT. Perhaps some initial E2F boost could 
be present in MYCN-low cells but the data does seem to indicate that the decision is 
already done at the beginning of the cell cycle. It is still not possible to exclude that 
some events happening in G2/M might be involved in dictating the differences observed 
in G1 early. The mechanism of how MYCN can cause alteration of SKP2 and E2F1 
could be transcriptional as found previously by others (Bell, Lunec et al. 2007, Bretones, 
Acosta et al. 2011) and the hyper-phosphorylation of Rb might be due as well to the 
overexpression of CDK4 (Gogolin, Ehemann et al. 2013). However it is interesting to 
point out that at least for the neuroblastoma system, the classical cell cycle inhibitors 
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(p21 and p27) might not be strongly involved in favoring the G0-like state but rather its 
maintenance. The chain of events could hypothesized as follows: an early Rb 
phosphorylation via CDK4 could lead to a fast E2F1 activation and promotion of a higher 
SKP2 boost already present in higher levels and therefore the destruction of some X 
inhibitor which might be playing the role in favoring the G0-like state, and all of this 
should be happening at the beginning of the cell cycle. However CDK4 do require Cyclin 
D1 as partner for activation, so one possibility is that MYCN could cooperate with 
mitogenic signals to start its early actions and favoring cell cycle commitment. To test 
this hypothesis, we first did an attempt to identify a single growth factor that could induce 
neuroblastoma cell growth. The reason is to more specifically track the effects to a 
particular pathway since serum stimulation is a myriad of different signals with multiple 
unspecific events. For the experiment, cells were starved for 24 hrs and then stimulated 
for additional 24 hrs with specific growth factors as shown in Figure 33. Viable attached 
(left panel) and floating (right panel) cells were counted using FACS.  
 
	
Figure 33 Growth factor stimulation of IMR5/75 cells. Left panel: Attached viable cells counted by 
FACS after 24hr serum starvation followed by specific growth factor stimulation. Right panel: viable cells 
from the same experiment in the supernatant. 
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Surprisingly from the list of growth factors used (in addition to TRAIL and TGF-beta as 
negative controls) the cells fail to proliferate and the effects were similar to the starvation 
condition. Of note, for this particular experiment, higher doses of growth factors were 
given as compared to values published in literature. The negative results might be due 
to very specific combination of growth factors required by the neuroblastoma cells. 
Given these results another approach was taken instead, in this case signaling inhibitors 
were used to test if specific signaling components cooperate with MYCN to favor cell 
cycle commitment in G1 early 
Cells were treated for 30 or 60 min with specific inhibitors in the presence of serum, and 
the phosphorylation of the target protein was measured by western blot. Titration of 
different doses on IMR5/75 cells revealed the amount of inhibitor needed to shut down a 
specific pathway. The inhibitors used were MEK, PI3K, AKT and PDK and as control 
serum starvation was performed to evaluate the reduction of ERK phosphorylation. 
(Figure 34)	
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Figure 34 Western blots of phospho proteins involved in MAPK and AKT signaling after inhibitors 
treatment. A) and B) cells treated with different doses of MEKi and PI3Ki in presence of serum for 30 and 
60 min. C) and D) cells treated for 30 min with AKTi and PDKi. E) Serum starvation for 30 min and pERK 
measurements. (Experiment performed in collaboration with Dmytro Dvornikov). 	
The results show that in general for most of the inhibitors, the dose needed to shut down 
the signaling pathway to 50-80% is around 1-4 µM, with the exception of the PDK 
inhibitor that with 0.5 µM dose was enough to block almost 90% of Akt phosphorylation. 
Once identified the dose, a quick experiment was performed to determine toxicity and 
effects on the cell cycle of MYCN-high cells. Cells were treated with relatively high 
doses of the inhibitors and E2F-d2GFP and DNA content was measured after 24 hrs 
and 56 hrs, and results are shown in Figure 35: 
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Figure 35 Screen of inhibitors in the E2F-d2GFP cells. Cells were treated for the times shown fixed 
and stained for DNA content. 	
10.5.2. MEK inhibition overrides the initial E2F promoter activity in G1 
early 
The treatments show that MEK and AKT inhibitors do not perturb the qualitative cell 
cycle pattern in the time points tested in comparison to the control. However, for the 
PI3Ki and PDKi, strong cell dead was observed together with cell cycle arrest for the 
surviving cells. PDKi seemed to induce G2 arrest, which became evident at 56 hrs, and 
for the PI3Ki, the cell cycle arrest occurred at G1 and G2. In both situations, E2F-d2GFP 
levels were reduced. Even though MEKi and AKTi did not show strong differences in cell 
cycle, it is still possible that it can G0-like depending on the dose. For that reason, the 
experiments were repeated with the Cdt1-degron and E2F1-d2GFP cell line by using the 
MEKi together with E2Fi and CDK4i used here as controls. The purpose was to 
investigate the effects of this inhibitors in G1 early and the relationship with G0-like 
state. 
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Figure 36 Selected set of inhibitors used to evaluate the G0-like population. Cells were incubated  
separately for 24 hr with each of the inhibitors shown. 	
As shown in Figure 36, all the inhibitors tested affected the G0-like population although 
in different ways. The CDK4i induced a strong G0-like arrest, reproducing the effects 
caused by MYCN reduction as expected. The E2Fi induced G0-like arrest as expected 
but interestingly the initial E2F1 boost was preserved in the doses tested. This finding 
was surprising as it was expected that the E2F1 inhibitor would abolish E2F1 in G1 early 
as well. Both MEK inhibitors (U0126 and the more recent one PD0325901) did show an 
interesting pattern. As previously observed with the serum starvation experiment (Figure 
23), the inhibitors managed to override the initial E2F boost, so it does seem as if cells 
do not increase E2F promoter activity and only Cdt1-degron is accumulated reaching 
the G0-like state. Together this might indicate that mitogen signaling might cooperate 
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with MYCN scape the G0-like state. As explained in the previous experiments, it is still 
unclear why MYCN-low cells might have this initial E2F1 boost and still enter G0-like 
state at least from the trajectories observed and from the snapshot data. However there 
might be the possibility that the picture for most of the cells is a start in G1 early with no 
E2F boost and only Cdt1-degron accumulation. In some other cells this initial boost is 
necessary to scape the G0-like state. It is interesting to speculate that MYCN might 
provide this initial E2F1 boost that prevents cells to reach the G0-like state. Apparently 
this initial boost is also not overridden by CDK4 or E2F1 inhibition so there might 
another control mechanisms driven by mitogenic signaling that might be responsible for 
the G1 early response. 
 
10.6. Analysis of Gene expression profiles from sorted cells identify key 
regulators of G0-like state in MYCN-high cells 
10.6.1. Sorted cells using cell cycle markers is a better alternative than 
cell synchronization  
To answer this question, RNA sequencing from the different populations was performed. 
Cells were cultivated under exponential growth, collected, re-suspend it in buffer with 
RNAse inhibitor to prevent RNA degradation and sorted according to the intensities of 
the 4 classical populations: G1 early, G1, late, G0-like and S/G2. The dead cells were 
excluded via TOPRO-3 staining. The same procedure was performed for cells in the 
MYCN-low condition and the collected cells were snap-frozen in liquid nitrogen for 
further RNA extraction and sequencing. The gating scheme for the sorting procedure is 
illustrated in Figure 37.  An important aspect to note is that the gates in this case are 
relatively arbitrary since the clustering algorithm is not available on the sorting machine. 
For setting the G1 early gate for example, it was important to only gate the populations 
that are colorless, since cells start to accumulate Cdt1-degron or E2F1-d2GFP relatively 
fast after cell division as observed in microscopy trajectories. To our knowledge it is the 
first time that unperturbed cell cycle dependent data is generated in neuroblastoma 
cells. Especially since previous cell cycle studies only used time courses of chemically 
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synchronized cells, which was discussed before to be an important source of artifacts. 
An additional advantage of this type of data is that it allows to compare to previous gene 
expression profiles obtained for G0 or quiescent cells. The reporters allows direct 
visualization of the G0-like population in contrast to the CDK2 reporter study where it 
was only possible to detect the G0-like cells after normalizing nucleus and cytoplasmic 
intensity therefore not suitable for cell sorting. 
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Figure 37 Sorting scheme of Samples used for RNA sequencing. (See text for details). 	
After data processing (Reads aligning, calculation of expression values) the samples per 
each population were compared as MYCN-high vs MYCN-low to calculate the 
A
B
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differentially expressed genes. Genes were filtered by 0.1 FDR (false discovery rate) 
and 0.5 log2 fold change. Around 1119 genes were found to be differentially expressed 
in G1 early upon reduction of MYCN. This population represents the one with largest 
number of differentially expressed genes in G1 (Figure 38 A).  
 
	
Figure 38 Enrichment analysis of the differentially expressed genes in G1 sub-phases. A) Ven 
diagram plot illustrating genes commonly regulated among the different sub-phases. Right panel: Table 
showing the pathways enriched in the different populations. Only 4 populations showed significant 
enrichment. (RNAseq procedure performed by Tatjana Ryl and RNAseq data processing in collaboration 
with Chunxuan Shao). 	
10.6.2. G0-like transcriptional program under MYCN control is distinct 
from mitogen-starvation program in fibroblasts and stem cells 
A Venn diagram was performed to compare the number of genes that are exclusively 
regulated in each of the G1 sub-phases as shown in Figure 38A. 130 genes are involved 
in all of the sub-phases with only 80 genes being exclusively regulated in the G0-like 
state. 637 genes are exclusively regulated in G1 early. Gene enrichment analysis is a 
common method to obtain a global picture of the gene function from a set of genes. The 
analysis was performed with the DAVID platform selecting the KEGG pathway option 
(Jiao, Sherman et al. 2012).  The results are shown in Figure 38 (right panel). The first 
table shows the pathway enrichment in the 80 only G0-like and 637 G1 early genes. For 
the G0-like genes, the ribosome pathway was enriched, which relates to genes involved 
A G1 early G0-like
G1 late
Population (unique) KEGG pathway p-value (Benjamini)
G0-like Ribosome  0.05
G1 early DNA replication, Mismatch repair,
Ribosome biogenesis, Cell cycle  0.05
Population KEGG pathway p-value (Benjamini)
G1 early DNA replication, Cell cycle  0.05
G1 late PI3K-Akt/MAPK signaling pathway 0.4
G0-like Pathways in Cancer (TGF-b, CDK4, Bcl) 0.08
S/G2 p53 signaling pathway 0.6
Unsorted DNA replication, Cell cycle  0.05
KEGG enrichment all populations
KEGG enrichment unique genes
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in translation and protein synthesis. As for the case of G1 early, genes involved in 
multiple processes, such as DNA replication and DNA repair were enriched. Of note, the 
DNA repair genes might be an interesting finding since it has been proposed that cells 
could enter the G0-like state due to random DNA damage (Spencer, Cappell et al. 
2013), so one hypothesis could be that MYCN skips G0-like state with the influence of a 
more effective repair machinery (A topic that was addressed in Tatjana Ryl’s 
dissertation). When evaluating the pathway enrichment of the separate populations, no 
significant pathways were found with the exception of G1 early and unsorted cells. The 
information provided by pathway enrichment was not particularly useful to tease out the 
difference between G1 early and G0-like. Another option is to compare the G0-like 
differentially expressed genes with respect to G0 or quiescent cells expression profiles 
from published data to tease out common regulatory mechanisms. Two studies 
(Venezia, Merchant et al. 2004, Coller, Sang et al. 2006) generated comprehensive 
expression profiles of fibroblasts and hematopoietic stem cells under quiescence. The 
procedure to generate quiescence was mitogen starvation and contact inhibition for the 
fibroblast study and induction of proliferation and then collection of quiescent cells for 
the stem cell study. To test the hypothesis if the G0-like state caused by MYCN 
withdrawal has commonalities with the genes differentially regulated in other quiescent 
states, we compared the genes from G1 early and G0-like vs the list of genes found in 
the other studies. The results are shown in Figure 39: 
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Figure 39 Comparison of differentially expressed G0-like genes in neuroblastoma versus 
published data. (See text for details). 	
Surprisingly very few genes were conserved among the different datasets. In Mitogen 
starvation for a short period (Figure 39A), the data shows that as few as 2 genes were 
shared with G0-like gene set. For the G1 early case, the overlap is also not evident. The 
same case it is observed for the mitogen starvation condition for longer times (around 2 
weeks) (Figure 39B). Lastly, the stem cell data does not show any gene in common with 
the G0-like state. This results suggest that the genes affected by MYCN in the context of 
the G0-like state could be essentially different by the program employed by other cells 
when arresting in quiescence. This supports the theory that quiescence or G0-like state 
is an indistinguishable state with potentially different transcriptional programs. 
The last analysis indicates, that a set of genes might be specifically acting in concert 
with MYCN preventing the cells to enter the G0-like state, which might differ from the 
genes involved in the maintenance of the G0 state in other cells. Another approach to 
look at the expression data is by differential expression of genes by cell cycle phase 
rather than MYCN status. In this approach, a pairwise comparison is made between 
phases that are close in the transition. For example, one could determine the 
differentially expressed genes of G1 early vs G1 late phase. And the genes could be 
compared by visual inspection among conditions such as MYCN levels. This approach 
A
G0 program G1 early
G0-like
G0-program(late) G1 early
G0-like
G0-Stem cell G1 early
G0-like
Population Genes
G1 early
CCNB1, CEBPD, RRAGA,
RCC1, GGH, LMNB1,
PLCB4, CPE, KIAA0101,
SERPINF1, ITPR1, TPM1
G0-like ITGA1, F3
Population Genes
G1 early CCNB1, PCNA, H2AFZMCM4, PRDM5
Population Genes
G1 early
TRIO, CCNE1, MLF1,
COL6A2, RALGDS, ASNA1,
ATF2, ALCAM, E2F5,
ITGA9, TWIST1
G0-like FAS ANK2
B C
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was applied here to identify the genes responsible for the transitions, with specific focus 
on G1 early to G1 late transition and G1 late to G0-like.  
10.6.3. Outlook: RABL6, potential new MYCN-driven regulator of cell 
cycle commitment  
The analysis of differential expression was carried out as before with DSeq2 platform.  
The obtained list of genes was 3 per each MYCN condition. With the list of differentially 
expressed genes another analysis was performed. To perform this analysis, Ingenuity 
Pathway Analysis tool was used. (Kramer, Green et al. 2014). This platform performs an 
analysis called causal network analysis. This analysis is based on a proprietary 
database that stores experimental observations of nearly 5 million findings manually 
curated from literature and different databases. The network contains ∼40.000 nodes 
representing mostly genes, proteins, chemical compounds, microRNA molecules and 
biological functions. The nodes are connected by ∼1’480.000 edges representing 
cause–effect relationships related to expression, transcription, activation, molecular 
modification and transport as well as binding events. In some cases the edges have a 
causal direction, activating or inhibiting. Based on this data set, statistical analysis is 
performed (Z-score calculation) to predict based on the list of differentially regulated 
genes which potential regulator has the highest number of interactions (Kramer, Green 
et al. 2014). The results for the different transitions are shown in Figure 40. The data 
shows some interesting features. 
 
Figure 40. Upstream regulator analysis performed Ingenuity Pathway analysis suite 
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The transition from G1 early to G1 late exhibits some differences between MYCN-high 
vs. low conditions. For the case of MYCN-high cells, Cyclin D1 (CCND1) is activated 
which correlates with growth signaling activation. Interestingly, CDKN1A (p21) is also 
activated together with E2F4. Surprisingly these two genes are involved in the 
quiescence phenotype. Two more genes are additionally activated, PTGER2 and 
RABL6. The RABL6 gene is an interesting candidate since it has been shown to prevent 
G1/S arrest (Hagen, Muniz et al. 2014). As for the case of MYCN-low cells, E2F1 and 
Cyclin D1 are inhibited, with E2F4 and p21 enriched but no sign for activation. The 
transition to G0-like also exhibits some interesting properties. MYCN-high cells unlike 
MYCN-low preserve the activation of E2F1 and CCND1, potentially providing an 
advantage to scape the G0-like state as compared to MYCN-low cells. The G1 late to 
S/G2 transition shows that RABL6 is inhibited in the MYCN-low condition.  
 The results shown in this thesis seems to point to an special mechanisms of how 
MYCN-high cells avoid the G0-like state and therefore the increase in the growth rate. 
Cells after division could potentially have acquired an advantage from the previous cell 
cycle. MYCN-high cells start proliferation similarly than MYCN-low cells, but RABL6 
activation is more predominant leading to inactivation of p16, which is a well-known 
inhibitor of CDK4. This inactivation might lead to even stronger Rb phosphorylation 
observed at the moment of birth. As a consequence, this leads to an E2F1 increase, 
which could protect cells in case they arrive to the G0-like state. SKP2, on the other 
hand, might be also playing a role by further degrading p16. Finally, mitogen signaling in 
cooperation with MYCN might favor the activation of RABL6, which occurs at the 
beginning of the cell cycle. The initial E2F boost might be just a consequence of high 
levels of CDK4, which are probably not sufficient for cells to cross the restriction point 
and therefore leading cells entering the G0-like state (and perhaps leaving this state at 
different rates). As an outlook, testing the role of p16 and RABL6 will be crucial for the 
understanding of MYCN’s role in the commitment to cell cycle at G1 early. 
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Figure 41 Proposed mechanism for G0-like scape in MYCN-high cells 	
10.7. MYCN-high cells are highly sensitive to ROS imbalances 
10.7.1. MYCN-high cells are strongly addicted to the amino acid 
cystine 
Another aspect of the oncogenic properties of MYCN is cell metabolism. To investigate 
metabolic vulnerabilities of MYCN-high cells we first measure amino acid concentrations 
via GC/MS protocol. The intention of this measurement was to eavluate if potentially 
other aminoacids are essential specifically for MYCN-high cells. This is based on 
previous finding showing a strong depedence of c-MYC and MYCN high cells on 
glutamine metabolism (Ren, Yue et al. 2015).  
In the course of analyzing the global amino acid metabolism in the presence of MYCN, 
we measured the intracellular amino acid levels in IMR5/75 MYCN-amplified cells 
(Figure 42A). We sought to determine whether MYCN levels could affect amino acid 
concentrations. The results show that MYCN-low cells exhibited lowered intracellular 
levels of almost all amino acids by at least 2-fold. Treatment of cells with the c-MYC/Max 
inhibitor 10058-F4 that targets MYCN/max interaction yielded similar results (Figure 
42A). In particular, cysteine levels were drastically lowered by almost ten-fold when 
comparing MYCN-high and MYCN-low cells and by 4-fold in DMSO vs 10058-F4-treated 
cells. Single amino acid depletion revealed that MYCN-high cells are drastically 
P PP
MAPK
signaling
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sensitive to cystine deprivation, (oxidized form of aminoacid cysteine present in the 
medium) causing massive cell death whereas MYCN-low cells remained unaffected 
(Figure 42B). Inhibition of MYCN prevented cystine deprivation-mediated cell death. 
Glutamine deprivation impaired MYCN-high cell viability but much less pronounced as 
compared to cystine deprivation. Microscopy images shows the massive cell dead after 
cystine deprivation (Figure 42C). Together this indicates that neuroblastoma cell lines 
with increased MYCN levels evaluated here, are highly dependent on cystine, the 
precursor of cysteine,  for cell survival. 
	
Figure 42 Analyses of Amino Acid Uptake, and Strong Addiction of MYCN-Amplified 
Neuroblastoma Cells to Cysteine (Reduced Form of Cystine Presence in Cell Culture Medium)  (A) 
Quantification of intracellular amino acid levels. MYCN was either inhibited using 30 µM MYCN inhibitor 
(10058-F4), interfere with MYC/MAX interaction, or reduced by MYCN-shRNA-Tet-inducible system in 
IMR5/75 neuroblastoma cells for 4 days. * p < 0.05, *** p < 0.001 (t-test), indicating statistical significance. 
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Data are presented as an average of six independent samples. (B) Standardized cell viability of 
knockdown and inhibitor treated IMR5/75 sh-MYCN neuroblastoma cells. Data are presented as an 
average of triplicates and normalized to MYCN-high NT or DMSO control (full medium). (C) Light 
microscopic pictures representing IMR5/75 neuroblastoma cells in the presence or absence of cystine 
(oxidized form of amino acid cysteine) in cell culture medium for 24 hr. MYCN level was reduced using 
MYCN-shRNA-Tet-inducible system (left) or cells treated with MYCN inhibitor prior to the cystine 
starvation (right). In both conditions the picture was taken 24 hr post cystine starvation. Massive cell death 
can be observed upon cystine starvation in cells expressing high-level of MYCN (left). Scale bar: 50 µm.  
(Data was acquired in collaboration with Hamed Alborzinia) 
 
We observed that MYCN-high cells accumulate large amounts of cysteine compared 
with MYC-low cells (Fig. 1A-B). The dual role of cysteine consists of protein synthesis 
and as a crucial precursor of GSH production. To examine potential synthetic lethal 
interactions of MYCN with metabolic pathways, data mining from a previously executed 
siRNA screen was performed. The screen was initially done by Sina Gogolin from Frank 
Westermman lab and the data is presented with her permission. The screen was carried 
out in 384-well format by transfecting IMR5/75 cells in triplicate wells, each with three 
different siRNAs targeting a single gene. Several candidate hits in metabolic processes 
were found to be significantly lethal in MYCN-high condition, in particular genes involved 
in the GSH biosynthesis pathway, lipid peroxidation, and glycolysis. We found GSR and 
GSTM1 to cause synthetic lethality upon downregulation in IMR5/75 cells (Figure 43A). 
Interestingly, we observed GPX6 to be synthetic lethal in the same context, and the 
effects are compared to GAPDH as control. 
 
10.7.2. Cystine deprivation leads to ROS production and cell death 
Intracellular measurements of glutathione levels revealed a 2-fold increase in IMR5/75 
cells (Figure 43B). Knockdown and pharmacological inhibition of MYCN resulted in 
substantial reduction of intracellular GSH levels correlated with low cysteine levels 
(Figure 43B). Supplementing cystine-free medium with glutathione or cysteine preserved 
cell integrity in cystine-deprived cells overexpressing MYCN (Figure 43D). Glutathione 
maintains redox balance by eliminating ROS and counteracting its deleterious effects. 
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ROS are produced mainly by the mitochondrial respiratory chain and in some cases by 
cytosolic NADPH oxidases (NOXs) (Gorrini, Harris et al. 2013)To investigate the 
mitochondrial ROS production, we used CellROX staining. We observed that ROS 
levels are significantly lower in MYCN-high cells (Figure 43C). 16 h after cystine 
deprivation, mitochondrial ROS levels increased about 2-fold relative to basal levels in 
MYCN-high cells (Figure 43C). Together the results show that ROS can trigger cell 
death specifically in MYCN-high cells under cystine or GSH reduction. 
 
	
Figure 43 GSH pathway is overly active in MYCN-high cells to detoxify ROS. A) High throughput 
siRNA synthetic lethality screen, clearly indicating that enzymes from GSH pathway are synthetic lethal 
with MYCN. The bar plot shows the viability in IMR5/75 cells expressing high and low levels of MYCN. 3 
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different siRNAs sequences were used per gene for this experiment. GAPDH was used as a negative 
control. B) Intracellular analysis of glutathione level in IMR5/75 neuroblastoma cells using GC/MS. MYCN 
level was either reduced MYCN-shRNA Tet-inducible systems or inhibited by 10058-F4 MYCN inhibitor. 
C) Quantification of intracellular of level ROS in IMR5/75 neuroblastoma cells, in the presence or absence 
of cystine for 24 hr. MYCN level was reduced using shRNA-Tet-inducible system in IMR5/75 
neuroblastoma cells. D) Standardized cell viability of MYCN-amplified IMR5/75 neuroblastoma cells in the 
presence (indicated as Full), absence of cystine (indicated as –Cystine), in the absence of cystine but in 
the presence of GSH in the medium (indicated as –Cystine/+GSH), and in the absence of cystine but in 
the presence of cysteine in the medium (indicated as –Cystine/+Cys) for 24 hr. Data are presented as an 
average of triplicates. (Data was acquired in collaboration with Hamed Alborzinia) 	
10.7.3. MYCN sensitizes cells to ferroptosis under cystine deprivation 
Cystine deprivation induced massive cell death in MYCN-high cells. To evaluate the 
mechanism of cell death, we inhibited apoptosis and ferroptosis under cystine 
deprivation conditions (Figure 44A). We applied apoptosis and autophagy inihibitors z-
VAD-fmk, and Ferrostatin-1. Only for the case of Ferrostatin-1, we could substantially 
rescued MYCN-high cells under cystine deprivation (Figure 44A). This result suggests a 
novel association of MYCN and ferroptosis. The ferroptosis inducer erastin that causes 
GSH depletion was used here to test sensitivity of MYC-high cells to ferroptosis. Indeed, 
we confirmed that erastin triggers ferroptosis exclusively in MYCN-high cells (Figure 44B 
and 44C).  
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Figure 44 . Cystine Depletion Triggers Ferroptosis-Dependant Cell Death. A) Standardized cell 
viability of MYCN-amplified neuroblastoma cells in the presence or absence of cystine, and co-treated 
with 50 µM of z-VAD-fmk (z-VAD), a broad pan-caspase inhibitor and DMSO control for 24 hr. Data 
presented as an average of triplicates and standardized to NT (full medium). Right panel: Standardized 
cell viability of MYCN-amplified neuroblastoma cells in the presence or absence of cystine, and 5 µM 
ferrostatine-1 for 24 hr. Single dose treatment of Erastin in IMR5/75 B) and C) Tet21N cells either with 
MYC inhibitor treatment or MYCN induction. Light microscopic pictures representing MYCN-amplified 
neuroblastoma cells, Scale bar: 50 µm. (Data was acquired in collaboration with Hamed Alborzinia) 
 
11. Discussion 
In neuroblastoma, MYCN promotes uncontrolled proliferation leading to high-risk and 
poor prognosis tumors (Cheung, Murray et al. 2013). The role of MYCN in cancer has 
been widely studied specially in regulation of proliferation, however the exact 
mechanism of how MYCN oncogene regulates cell cycle remains poorly understood 
(Huang and Weiss 2013). Here we used neuroblastoma as a model to understand cell 
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cycle regulation driven by MYCN, in particular the G1 transition that has been previously 
shown to be strongly influenced by MYCN (Gogolin, Ehemann et al. 2013). IMR5/75 
cells (carrying 75 copies of MYCN) with a tet inducible system for MYCN shRNA were 
used to downregulate MYCN levels at the point of affecting proliferation denoted here by 
MYCN-low condition and MYCN-high for the normal level situation. One of the caveats 
of the study is that MYCN reduction is mild as shown in Figure 11A. A personal 
communication from Frank Westermann relates that further reduction of MYCN to lower 
levels leads to strong cell death. Despite these limitations, the system still shows a delay 
in proliferation, which was observed in the growth kinetics. Previous experiments in 
mouse fibroblasts showed that enforced expression of c-MYC could lead to cell cycle 
entry in quiescence cells (Armelin, Armelin et al. 1984). The effects were enough to 
block exit from cell cycle, and in the case of embryos this was completely independent 
of growth factors (Piedra, Delgado et al. 2002). However these studies relied on a more 
phenotypic definition of quiescence. Our data showed that MYCN cells can increase the 
number of proliferating cells so as probably showed for the c-MYC case, there was the 
suspicion that MYCN could also foster the exit from quiescence. The problem as 
discussed in the introduction, is that the quiescence phenotype is only defined as a cell 
cycle arrest in the absence of mitogens. The study from (Spencer, Cappell et al. 2013) 
shed light on the dynamical properties of quiescence (or more accurately defined the 
G0-like state). One of the highlights of the study is that for the first time it was possible to 
observe the entry into G0-like in real time, and the realization that cells could 
stochastically enter this state by influence of p21 levels from the previous cell cycle. 
Therefore it was safe to assume that if c-MYC could alter the quiescence state, then 
having markers to detect quiescence and evaluating the effects of its homologous 
MYCN, one could learn something about the mechanism. Here we found that E2F-
d2GFP which was observed to be a marker for the restriction point, when in combination 
with the Cdt1-degron reporter allowed the visualization of the G0-like state. This came 
as a surprise since it was not expected that the combination of the reporters could 
clearly unmask a population present at high Cdt1-degron levels and low E2F1-d2GFP.  
Further experimental validations of this population done in this thesis showed a similar 
result observed by (Spencer, Cappell et al. 2013). This population was transient and 
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reversible in nature. One of the important findings with respect to this population is the 
fact that it happens in the area defined here as G1 late. This is of relevance since just 
based on E2F-d2GFP levels, the G0-like and G1 early states are not distinguishable.  
This goes in agreement, with c-MYC knockout studies that found elongated G1 and G2 
with lower CDK4 and CDK2 activity. The experiments showed that either c-MYC or 
MYCN could speed up the cell cycle of slow proliferating cells (Berns, Hijmans et al. 
2000). Therefore, the evidence in our experiments shows that the reason why MYCN as 
well might promote acceleration of the cell cycle is by preventing cells to enter the G0-
like state, and this was only possible by the finding of the reporter combination that 
allowed the visualization of the G0-like state.  
The colony sorting procedure showed as well an interesting result. When sorting G0-like 
cells, the colony results showed that MYCN-low cells generate less number of colonies 
as compared to the MYCN-high cells. The same goes for cells sorted from the S/G2 
population. When comparing G0-like and S/G2 in both conditions, G0-like cells 
generated less number of colonies. One possible explanation is survival, perhaps G0-
like cells could be more sensitive to stressors such as sorting, which is a mechanical 
force applied onto the cells membrane. However as shown in the example pictures of 
colonies, it seems that G0-like cell colonies are smaller. This could lead to an alternative 
explanation. It might be possible that G0-like cells carry an inheritance factor (MYCN?) 
that is passed onto daughter cells rendering to a homogeneous population. This 
hypothesis could be supported by a recent study (Sandler, Mizrahi et al. 2015) showing 
that cell division times of cousin cells are correlated. In the study, live cell imaging and 
tracking was performed over 60 generations, and several hundreds of cell pairs were 
analyzed. Interestingly, mother daughter correlation was low, but cousins were highly 
correlated. One explanation was that the circadian clock could exert an influence in the 
cell cycle duration. This could suggest that even though, cell cycle regulators are 
probably reset in each cell cycle some inheritance is still present and manifest in later 
generations. The only way to tease out this question will be by performing lineage 
analysis of IMR5/75 cells with the reporters used in this thesis. 
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When performing the FACS analysis it was interesting to observe that in both cases, 
MYCN-low and MYCN-high cells do have an initial boost of E2F1 levels. This was 
clearly observed in the FACS data and slightly clear in the microscopy trajectories due 
to the limitations of tracking IMR5/75 cells. The presence of initial E2F promoter activity 
which still leads to the G0-like state seems to go in disagreement to the results shown 
by (Spencer, Cappell et al. 2013). In Figure S3A of that study, the combination Cdt1-
degron and CDK2 reporter showed that cells with very high Cdt1 levels exhibit no CDK2 
activity. However the study published by (Dong, Maddali et al. 2014) showed that 
quiescent cells might still have some weak E2F1 responses. In their paper, the 
quiescence phenotype was not defined by absence of E2F1 activity but rather due to the 
amplitude. So there is still possibility that G0-like cells even though CDK2 activity is not 
reached completely, some E2F1 promoter activity might be still present via stochastic 
activation from remaining free E2F1 free.  
Serum starvation treatment showed that cells could arrest in the G0-like state. This 
confirms that the state defined by MYCN withdrawal is related to the state defined as 
quiescence via mitogen withdrawal. However, it has been proposed that quiescence is 
controlled either by p21 (Spencer, Cappell et al. 2013) and p27 (Oki, Nishimura et al. 
2014). Knockdown of these inhibitors did not show any significant rescue of cells in the 
G0-like state. This result was unexpected since at least for epithelial cells and other cell 
systems, the G0-like state defined by mitogen withdrawal depended exclusively on p27, 
and in a newly generated reporter for quiescent cells is based on the degradation 
properties of p27 (Oki, Nishimura et al. 2014). Protein stainings also showed an 
accumulation of these inhibitors in the G0-like state (Figure 28A). One possibility as 
mentioned in the results section is that p21 and p27 might play a role in the 
maintenance of the G0-like state, but perhaps the initial decision to enter or not the G0-
like state might be influenced by other regulators. At least for the case of c-MYC, 
knockout of p21 or p27 in mouse embryos can still lead to cell cycle arrest when 
repressing c-MYC targets via a double negative mutant (Berns, Martins et al. 2000). 
This indicates that either p21 or p27 are dispensable for cell cycle arrest in the presence 
of MYCN.  
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Stainings of the different cell cycle regulators and the observation of their localization in 
the Cdt1-degron and E2F-d2GFP plot indicated that there is no influence of MYCN in 
where these regulators are expressed at least from the global behavior. Some 
regulators such as activated CDK2 phosphorylated in the residue Thr160 was 
surprisingly located in the G0-like region. A recent study showed that pCDK2 is 
controlling the passage through the restriction point and its phosphorylation is influenced 
by mitogens (Mueller, Huard et al. 2015). One reason could be experimental error, 
however 3 different antibodies were tested and they all generated the same results. 
Another possibility is that CDK2 activation might occur only in G1 late (Mueller, Huard et 
al. 2015), but when no sufficient CDK2 is activated, the arrest could be triggered and the 
levels be carried out to the G0-like state. The same situation was observed for MYCN. 
But in the case of MYCN, other factors such as localization and perhaps activation via 
phosphorylation might play additional role in having the full activity of MYCN (Huang and 
Weiss 2013). 
The slicing approach of the Cdt1-degron distributions and the histograms derived from it 
gave an important source of information. To our knowledge it was not shown before that 
cells in G1 early exhibited already high levels of pRb in the MYCN-high case. This leads 
to several consequences. Cells might be born with a relative advantage from the 
previous cell cycle and being committed even if growth factor signals are not present 
yet. However comparison of the distributions for the different cell cycle regulators did not 
show difference in the G2 levels. Perhaps another regulator might be involved. One 
candidate could be CDK4. Constant high levels of CDK4 as described for the case of 
MYCN, can lead to already phosphorylation events at the moment of birth. However as 
previously shown (Narasimha, Kaulich et al. 2014), CDK4 alone might prime cells for 
cell cycle entry via monophosphorylation but quantum hyperphosphorylation via CDK2 is 
still needed in G1 late. 
Another novelty of the work presented here is the use of diffusion maps to extract 
dynamics from snapshot data. As previously discussed in the introduction, one of the 
main caveats of cell cycle studies are the artifacts caused by cell synchronization. After 
validation of the reporters Cdt1-degron and E2F-d2GFP it was possible to set up a 
common cell cycle axis to use it as a frame of reference to calculate the dynamics of 
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different regulators. The results showed remarkably reproducibility with the microscopy 
traces validating the approach (Figure 31). The trajectories showed interesting 
dynamics. E2F1 protein was the one that peaked earlier in MYCN-high cells. This goes 
in accordance with the pRb bimodality at birth found via the slicing approach. The 
reason why perhaps pRb early boost was not detected in this analysis might be due to 
averaging effects when calculating the trajectories. One solution is to calculate DPT and 
analyze the trajectories in a distribution-wise manner.  That is an interesting analysis for 
future improvements of the algorithm. Together, this shows that MYCN effects in G1 
early could be reduced to Rb phosphorylation and E2F1 expression. As for the case of 
E2F1, many mechanisms are involved in controlling not only protein stability and gene 
expression (Donjerkovic and Scott 2000) which makes the regulation complex, but 
perhaps just simply direct activation of the E2F1 promoter might be necessary for the 
intial boost. To our knowledge this has not been proven yet, so further experiments are 
needed to evaluate the different sites of the E2F1 promoter and their association with 
MYCN binding and activation. 
Inhibitors of cell cycle and mitogen signaling were used to validate the mechanism of 
arrest (Fig 36). CDK4 inhibition (LEE011) leads to accumulation of G0-like cells in 
MYCN-high cells resembling the effect of MYCN reduction, providing evidence for the 
CDK4 hypothesis. E2F inhibition with the HLM006474 inhibitor resulted in the same 
effect. MEK inhibitors U0126 and PD0325901 caused a different pattern of arrest. Cells 
accumulated uniformly on different levels of Cdt1 with no increase in E2F promoter 
activity. This might suggest that the initial boost of E2F activity might be related to 
correct functioning of MAPK cascade. More recently it has been proposed that targeting 
signaling pathways could be an effective therapy for neuroblastoma tumors.(Tanaka, 
Higashi et al. 2016). Data regarding ERK and MYCN is scarce, but early studies in c-
MYC showed that intact MAPK signaling is necessary for c-MYC phosphorylation which 
prevents its degradation (ref). One could speculate, that a similar situation could happen 
for MYCN, although more studies are needed in this area. Very recently, by using a 
combination of MEK and CDK4 inhibitors the authors induced strong reduction of tumor 
growth in neuroblastoma samples (Hart, Rader et al. 2016), this strongly supports the 
findings presented here, since inhibitors that only induce G0-like arrest such as CDK4 
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inhibitors might still allow the initial E2F boost. This could be a dangerous option since 
those cells could potentially leave G0-like and enter in S phase. 
To investigate the regulatory program of the different cell cycle states in G1, RNA-seq 
measurements of live-sorted populations was performed. Differential expression of 
genes was calculated based on MYCN-high versus low condition. Interestingly, G1 early 
showed the highest number of regulated genes among the different G1 populations. For 
the G0-like and G1 early populations only 80 and 637 were regulated exclusively on 
those populations. To gain further insight into genes involved in G0-like, comparison of 
gene lists were performed against previously published set of genes implicated in G0-
regulation in fibroblasts and stem cells. Interestingly very little overlap was found among 
MYCN regulated genes and genes involved in G0 arrest (e.g mitogen withdrawal) in all 
different gene lists. This result might suggest that a different regulatory program might 
be involved in allowing the entrance to G0-like under MYCN-low conditions, as 
compared to the classical G0 program. A different approach to tease out the regulatory 
machinery responsible for G0-like and MYCN was taken. This time differential 
expression analysis was performed by cell cycle phase, comparing groups such as G1 
early/G1 late, G1 late/G0-like and G1 late/S/G2. From the list of differentially regulated 
genes, Of note, RABL6 appeared to be activated in MYCN-high cells in the transition 
from G1 early to G1 late. This is an interesting prediction since the information about 
RABL6 (REBL1) is scarce. Very recent paper discussed the role of RABL6 in 
osteosarcoma, where it serves as a promoter of cell cycle entry. Inhibitor of RABL6 in 
this tumor induced G1 arrest (Tang, Ji et al. 2016). Another study found overexpression 
of RABL6 in around 67% of breast cancer samples (Montalbano, Jin et al. 2007). The 
mechanism of how RABL6 promotes cell growth is not known. This constitutes an 
interesting molecule that could be studied in more detail in the relationship with MYCN. 
The only data available about possible regulators interacting with RABL6 come from 
yeast-two hybrid studies (Tompkins, Hagen et al. 2006). One interesting regulator 
coming from this data set was p16, which has been shown to induce cell cycle arrest by 
inhibition of CDK4 in G1 early (Donjerkovic and Scott 2000).  
The model proposed here suggests that MYCN expression in G1 early leads to 
increased E2F1 and CDK4 levels, which lead to Rb phosphorylation. Apparently this 
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could be enogh for cells to prevent entry into quiescence state. MAPK pathway might 
prevent MYCN degradation, fostering the proliferative effects. RABL6 can serve as a 
potential target that together with MYCN could cooperate to inhibit p16, contributing as 
well to prevent G0-like entry. 
The MYC proto-oncogene is strongly involved in cancer proliferation and metabolism 
(Hanahan and Weinberg 2011). Several MYC-regulated genes participate in 
mitochondrial biogenesis, glutamine and glucose metabolism. An altered redox balance 
has been implicated in MYC-driven tumorigenesis as a strategy to cope with metabolic 
stress deriving from excessive proliferation (Cairns, Harris et al. 2011). Our studies have 
shown that MYC appears to enforce vulnerability to cystine deprivation and selectively 
induces cell death via ferroptosis. This mechanism of cell death is distinct from that of 
apoptosis and autophagy.  
MYC boosts intracellular amino acid levels and alters the expression of enzymes of 
amino acid metabolism (Zirath, Frenzel et al. 2013), though the detailed regulation 
process remains unclear. One possibility seems to be by driving protein synthesis 
through activation of ribosomal proteins and translation initiation factors (van Riggelen, 
Yetil et al. 2010). MYC cooperates with mammalian target of rapamycin (mTOR) and 
eukaryotic translation initiation factor 4E binding protein-1 (4EBP1) in regulating protein 
synthesis. Targeting mTOR has been suggested as a therapeutic approach in Myc-
driven hematological cancers (Pourdehnad, Truitt et al. 2013). Among the upregulated 
amino acids, we observed that the intracellular level of cysteine increased to almost ten-
fold in MYCN-high condition. Cysteine is the reducing agent of GSSH and mitigates 
ROS levels, which has mostly detrimental effects (Paulsen and Carroll 2013). Upon 
single amino acid deprivation we found that MYC/MYCN-high cells specifically undergo 
cell death when either cystine or glutamine is restricted. Glutamine deprivation has been 
shown to induce apoptosis in MYC-amplified cells (Wise, DeBerardinis et al. 2008, Qing, 
Li et al. 2012). We observed that cell death upon cystine deprivation is independent of 
media composition and strongly selective in MYCN-high cells. Consistent with our 
findings, inhibition of cystine uptake rather than glutamine deprivation seemed to target 
triple-negative breast cancer tumors more effectively (Timmerman, Holton et al. 2013).  
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The role of ROS in cancer development is not yet fully understood. On one hand, ROS 
could influence cell signaling, but when in excess it can contribute to DNA damage and, 
as shown more recently, to lipid peroxidation and ferroptosis (Gorrini, Harris et al. 2013, 
Sabharwal and Schumacker 2014). GSH is the main antioxidant in mammalian cells, 
and its function is tightly coupled to cystine availability. We found that MYCN-high cells 
exhibited increased levels of GSH, while mitochondrial ROS remained almost identical in 
MYCN-high/low conditions. Expression of MYC was shown to induce ROS, whereas it 
lowered the levels via activation of NRF2 and its target genes if endogenously 
expressed (DeNicola, Karreth et al. 2011). We found that mitochondrial ROS increased 
specifically in MYCN-high cells under cystine deprivation. Adding glutathione prevented 
cell death in MYCN-high cells.  
We systematically tested the mechanisms of cell death involved in cystine deprivation. 
Using chemical inhibitor of apoptosis we could not prevent cell death under cystine 
deprivation conditions. Only ferrostatin-1 could completely restore cell viability. This 
evidence was further confirmed by treatment with erastin showing that MYC/MYCN-high 
cells selectively undergo ferroptosis. These results are supported by previous evidence 
showing that reduction of cystine uptake induces ferroptosis (Jiang, Kon et al. 2015). We 
found that MYC might enhance sensitivity to ferroptosis via multiple mechanisms. Of 
note, glutaminolysis and possibly high iron uptake (Wu, Polack et al. 1999, O'Donnell, 
Yu et al. 2006, Gao, Monian et al. 2015) together with a strong dependence on the 
glutathione pathway could lead to higher susceptibility of MYC-driven tumors to 
ferroptosis. We propose that activation of ferroptosis can be exploited as a new 
therapeutic approach to target MYC-driven tumors 
  
MYCN modulates the restriction point and ferroptosis in Neuroblastoma [Pick	the	date] 	
96	
12. Conclusions 
In the present thesis, the mechanisms employed by MYCN to promote cell proliferation 
and sustain cell metabolism were explored. 
The results showed that MYCN reduces G1 length by preventing cells to enter in the 
G0-like state. The successful combination of Cd1-degron and E2F-d2GFP reporters 
allowed to visualize the G0-like state which is an important step for understanding the 
regulation of the restriction point in Neuroblastoma cells. 
MYCN seems to act specifically in G1 early at the moment of birth via increased Rb 
phosphorylation and early E2F1 expression. Cell cycle inhibitors p21 and p27 do not 
seem to play an important role in driving MYCN-low cells into the quiescence state. 
MEK inhibition revealed a strong synergy with MYCN at G1 early by promoting the intial 
E2F promoter boost. Perhaps a combined therapy of MEK inhibition with other cell cycle 
inhibitors such as CDK4 or E2F could be more effective in treating neuroblastomas, as 
recently suggested by (Hart, Rader et al. 2016) 
Gene expression profiles from G0-like cells originated by MYCN reduction do not share 
a significant number of differentially regulated genes with respect to other expression 
profiles of cells in quiescence. This suggest that the G0-like program is specific for cells 
addicted to MYCN. 
As an outlook, RABL6 seems to be a promissory target in controlling cell cycle 
commitment at G1 early. Further experiments are needed to confirm this hypothesis 
driven by the analysis of sorted RNA-seq data. 
 
. 
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